Card Inc

HEAD START AND EARLY HEAD START

STRENGTHENING DECENTRALIZED HEALTH SERVICE DELIVERY

HEAD START PROGRAM

HQ-GH15-1539, CARDNO: PUBLIC-PRIVATE PARTNERSHIPS IN PEPFAR COUNTRIES UNDER THE PRESIDENT?S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR)

HEAD START AND EARLY HEAD START

SMARTER MANAGEMENT AND RESOURCE USE FOR TODAY'S COMPLEX CARDIAC CARE (SMARTCARE)

HEAD START-FULL YEAR PART DAY HANDICAPPED TRAINING AND TECHNICAL ASSISTANCE

HEAD START AND EARLY HEAD START

HEAD START AND EARLY HEAD START

ODEP DISABILITY GRANTS

HEAD START AND EARLY HEAD START

COVID RELIEF FOR BIOFUEL PRODUCERS GRANTS

UNIVERSITE DE MONTREAL IBD GENETICS RESEARCH CENTER

ADMINISTRATION OF THE WAVE ENERGY CONVERTER PRIZE

THERAPEUTIC GROUP HOME AND LONG TERM FOSTER CARE PROGRAM FOR UNACCOMPANIED ALIEN CHILDREN

INNOVATIVE INTEGRATED 3-IN-1 INVERTER/ON BOARD CHARGER/AUXILIARY DC CONVERTER FOR ELECTRIFIED VEHICLE APPLICATIONS

DE-EE0008806 WITH RICARDO, INC. TITLED ''HIGH EFFICIENCY POWERTRAIN FOR HEAVY DUTY TRUCKS USING SILICON CARBIDE (SIC) INVERTER''.

TOWARDS VIRTUAL LABORATORY FOR OPTIMAL PATIENT-SPECIFIC CARDIAC RESYNCHRONIZATION

IDENTIFICATION OF THE IBD GENES ON CHROMOSOMES 3P AND 6P

DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY - ABSTRACT THE TECHNICAL CHALLENGES FACED BY PEDIATRIC CARDIOVASCULAR PHYSICIANS (SURGEONS AND INTERVENTIONALISTS ALIKE) HAVE LONG BEEN IGNORED, FORCING THEM TO USE DEVICES DESIGNED FOR ADULTS AND DIFFERENT CONDITIONS TO TREAT AILING BABIES WITH VERY SPECIFIC ANATOMICAL CONSIDERATIONS. ONE SUCH CASE IS IN THE SUSTAINED OPENING OF THE DUCTUS ARTERIOSUS, A NATURAL CONDUIT THAT EXISTS IN ALL NEWBORNS BUT CLOSES SHORTLY AFTER BIRTH. IN CERTAIN CONGENITAL HEART DEFECTS, IT IS CRUCIAL TO MAINTAIN DUCTUS PATENCY FOR THE NEWBORN TO SURVIVE WITHOUT SURGICAL INTERVENTION. THERE IS NO DUCTUS ARTERIOSUS STENT COMMERCIALLY AVAILABLE IN THE US. PEDIATRIC INTERVENTIONAL CARDIOLOGISTS CURRENTLY REPURPOSE ADULT STENTS FOR THE DUCTUS, AND ALL-CAUSE DUCTUS REINTERVENTION IS 47%. THE ALTERNATIVE IS OPEN-CHEST SURGERY ON A NEONATE TO PLACE A SHUNT THAT CARRIES A 13.1% RISK OF MORBIDITY AND 7.2% RISK OF MORTALITY IN THE US. STARLIGHT CARDIOVASCULAR PROPOSES CREATING AND COMMERCIALIZING THE FIRST FDA-APPROVED DUCTUS ARTERIOSUS STENT THAT IS SPECIFICALLY DESIGNED TO ADDRESS THE CHALLENGES FACING TREATING PHYSICIANS, INCLUDING A RIGHT-SIZED DELIVERY SYSTEM, END-TO-END COVERAGE OF THE DUCTUS, NAVIGATION AND DEPLOYMENT THROUGH TORTUOUS DUCTUS ANATOMY, AND PRECISE PLACEMENT TO AVOID STENT PROTRUSION INTO THE AORTA AND PULMONARY ARTERIES. A STENT DESIGNED AND TESTED SPECIFICALLY FOR THIS PURPOSE HAS THE POTENTIAL TO DECREASE REINTERVENTIONS, MORBIDITY, AND POTENTIALLY MORTALITY FOR BABIES WITH DUCTAL-DEPENDENT CIRCULATION. THE FEASIBILITY OF THE INNOVATIVE STENT SYSTEM DESIGNED FOR PEDIATRIC APPLICATIONS USING SELF-EXPANDING TECHNOLOGY WAS DEMONSTRATED IN A SUCCESSFUL PHASE I THROUGH NUMEROUS ROUNDS OF BENCH TESTING, PHYSICIAN EVALUATIONS, AND AN ANIMAL STUDY; AND THIS PHASE II APPLICATION PROPOSES FINALIZING THE STENT DESIGN AND COMPLETING PRECLINICAL TESTING NECESSARY FOR A CLINICAL TRIAL AND FDA APPROVAL. THROUGH RAPID ITERATIONS, STARLIGHT WILL BEGIN BY OPTIMIZING THE STENT SYSTEM FOR DESIGN CHARACTERISTICS AND MANUFACTURABILITY. STARLIGHT WILL THEN COMPLETE A CHRONIC GLP ANIMAL STUDY IN 16 NEWBORN LAMBS TO DEMONSTRATE STENT PATENCY OVER 180 DAYS. VERIFICATION AND VALIDATION (V&V) TESTING OF ALL ASPECTS OF THE STENT SYSTEM (INCLUDING BIOCOMPATIBILITY, STERILIZATION, AND MECHANICAL TESTING) WILL THEN BE PERFORMED IN ACCORDANCE WITH FDA GUIDANCE DOCUMENTS FOR ENDOVASCULAR STENTS. THIS PHASE II PROJECT WILL RESULT IN A FINALIZED DUCTUS ARTERIOSUS STENT SYSTEM DESIGN THAT HAS PASSED ALL OF THE NECESSARY PRECLINICAL TESTING REQUIRED FOR A CLINICAL TRIAL AND SUBSEQUENT FDA APPROVAL THROUGH THE HUMANITARIAN DEVICE EXEMPTION PATHWAY.

HEAD START AND EARLY HEAD START

ACCF-STS DATABASE COLLABORATION ON THE COMPARATIVE EFFECTIVENESS OF PCI AND CABG

2008 ANNOUNCEMENT OF AVAILABILITY OF FUNDS FOR TEN FAMILY PLANNING REGIONAL GENERAL TRAINING AND TECHNICAL ASSISTANCE PR

POISON CONTROL STABILIZATION AND ENHANCEMENT PROGRAM

NATIONAL TITLE X TRAINING & TA CENTER FOR FAMILY PLANNING SERVICE DELIVERY

STRITCH EMERGENCY RELIEF FUND - INSTITUTIONAL PORTION

2008 ANNOUNCEMENT OF AVAILABILITY OF FUNDS FOR TEN FAMILY PLANNING REGIONAL GENERAL TRAINING AND TECHNICAL ASSISTANCE PR

REGULATORY PLAN FOR TORVAD VENTRICULAR ASSIST SYSTEM

POISON CONTROL STABILIZATION AND ENHANCEMENT PROGRAM

STRITCH STUDENT EMERGENCY GRANT

AORTA BRAIN AND KIDNEY STRUCTURE AND FUNCTION IN THE AGES-REYKJAVIK STUDY

VITRACK: WEARABLE, ACCURATE, CONTINUOUS BLOOD PRESSURE MONITOR TO IMPROVE OUTCOMES IN HYPERTENSIVE DISEASES OF PREGNANCY - DYNOCARDIA, A TUFTS UNIVERSITY SCHOOL OF MEDICINE AND MASSACHUSETTS INSTITUTE OF TECHNOLOGY SPINOFF, IS ADDRESSING AN UNMET NEED FOR REAL-WORLD ACCURATE AND CONTINUOUS NON-INVASIVE BLOOD PRESSURE (BP) AND OTHER CARDIO-HEMODYNAMIC PARAMETERS. VITRACK™, A UNIQUE OPTOMECHANICAL SENSOR AND COMPUTER VISION TECHNOLOGY, IS THE FIRST TO MEASURE BEAT-TO-BEAT SYSTOLIC (SBP) AND DIASTOLIC BPS (DBP) IN REAL-WORLD SETTINGS WITH THE ACCURACY OF INVASIVE ARTERIAL PRESSURE WITHOUT EXTERNAL CALIBRATION, IRRESPECTIVE OF SUBJECT MOVEMENT OR WRIST POSITION RELATIVE TO THE HEART (HYDROSTATIC PRESSURE CHANGE). DYNOCARDIA IS EXPANDING INTO THE HOSPITAL MARKET AND EXPLORING ITS TECHNOLOGY'S POTENTIAL IN OTHER AREAS OF HEALTHCARE, PARTICULARLY IN MATERNAL HEALTH. DYNOCARDIA HAS SECURED AN SBIR PHASE II GRANT [PROJECT NUMBER: 1R44HL167356-01] TO STUDY THE EFFECTIVENESS OF VITRACK TECHNOLOGY IN ENSURING THE SAFETY AND WELL-BEING OF MOTHERS AND THEIR CHILDREN DURING PREGNANCY. I. PROJECT SUMMARY: VITRACK’S BEAT-TO-BEAT ACCURATE MEASUREMENTS, IRRESPECTIVE OF PATIENT MOVEMENT OR WRIST LEVEL TO THE HEART, PROVIDE THE PATIENT’S CIRCADIAN BP PATTERN, INCLUDING 24-HR MEAN BP, NIGHTTIME BP, AND BP VARIABILITY (BPV). IN ADDITION, VITRACK ALSO MEASURES HEART RATE, RESPIRATORY PARAMETERS, AND ADVANCED HEMODYNAMICS. THE HYPERTENSIVE DISEASES OF PREGNANCY (HDP) ARE A SIGNIFICANT CAUSE OF MORBIDITY AND MORTALITY. THE CURRENT STANDARD FOR MEASURING BP IN PREGNANT WOMEN IS THE PERIODIC USE OF OSCILLOMETRIC ARM-CUFF DEVICES. THE OSCILLOMETRIC DEVICES INDIRECTLY ESTIMATE SBP AND DBP BASED ON ARTERY WALL OSCILLATIONS DURING CUFF DEFLATION. MEASUREMENT ERRORS INHERENT TO THIS INDIRECT METHOD, PATIENT POSTURE/MOVEMENT, AND WRONG CUFF SIZE LEAD TO UNRELIABLE BP MEASUREMENTS IN 50% OF ROUTINE OFFICE VISITS. OSCILLOMETRIC DEVICE ERRORS ARE COMPOUNDED IN PREGNANT WOMEN DUE TO HEMODYNAMIC AND VASCULAR CHANGES THAT REDUCE OSCILLATIONS OF THE ARTERIAL WALL, RESULTING IN BP UNDERESTIMATION. IN CONTRAST, THESE HEMODYNAMIC CHANGES WILL HAVE LESS IMPACT ON VITRACK MEASUREMENTS BECAUSE IT UTILIZES PRESSURE-DEPENDENT SPATIOTEMPORAL SKIN DISPLACEMENT TO MEASURE SBP AND DBP DIRECTLY. IN ADDITION, RANDOM CLINIC MEASUREMENTS DURING ANTENATAL VISITS LEAD TO A 30% WRONG DIAGNOSIS OF HDP DUE TO WHITE COAT OR MASKED HYPERTENSION. IN ADDITION, THERE IS A NEED FOR REMOTE AND CONTINUOUS ACCURATE MEASUREMENT OF BP FOR PREDICTION AND EARLY DEDUCTION OF PREECLAMPSIA. THE CIRCADIAN BP PARAMETERS, SUCH AS 24-HR MEAN SBP, NIGHTTIME BP, AND BPV, ARE BETTER PREDICTORS OF PREECLAMPSIA THAN CLINIC BP MEASUREMENTS. VITRACK, THE FIRST STANDALONE, WEARABLE, CONNECTED DEVICE, CAN PROVIDE REMOTE, ACCURATE CIRCADIAN BP DATA FOR CORRECT DIAGNOSIS AND ENABLE PREDICTIVE MONITORING FOR BETTER OUTCOMES. IN PRECLINICAL, OUTPATIENT [VS. AUSCULTATORY METHOD], AND INPATIENT [VS. INVASIVE ARTERIAL PRESSURE], VITRACK MET FDA STANDARDS FOR ACCURACY. IN THIS SBIR PHASE II STUDY, WE ARE EXPANDING THE APPLICATION OF VITRACK IN HDP IN PARTNERSHIP WITH NYC HEALTH + HOSPITALS THAT SERVES UNDERSERVED POPULATIONS, A LARGE PERCENTAGE OF THEM NON-HISPANIC BLACK POPULATION AT HIGH RISK FOR HDP. THE AIMS OF THE STUDY ARE: SPECIFIC AIM (SA) 1: ASSESS THE ACCURACY OF VITRACK BP MEASUREMENTS (N=48). SA1(A): DETERMINE THE ACCURACY OF VITRACK MEASUREMENTS IN PREGNANT WOMEN (N=33) AS PER THE EUROPEAN SOCIETY OF HYPERTENSION INTERNATIONAL PROTOCOL-2010) [34]; SA1(B): DETERMINE ACCURACY IN SEVERE PREECLAMPSIA (N=15), DEFINED AS BP MEASUREMENT OF 170/110 OR MORE AND PROTEINURIA OF 500 MG OR MORE IN 24-HR. MILESTONE: VITRACK ACCURATELY MEASURES BP IN PREGNANT WOMEN, INCLUDING WOMEN WITH SEVERE PREECLAMPSIA. SA2: ASSESSMENT OF 24-HR BP WITH VITRACK (N=100). COLLECT 24-HR BP WITH VITRACK AND INTERMITTENT CUFF BP MEASUREMENTS AS PER STANDARD PRACTICE FROM THE CONTRALATERAL ARM; SA2(A): ASSESS TOLERABILITY/USABILITY AND RELIABILITY OF 24-HR BEAT-TO-BEAT BP IN UNCONSTRAINED SUBJECTS (N=20); SA2(B): COMPARE THE 24-HR BP PROFILE IN PREGNANT WOMEN WITH AND WITHOUT HDP (N=80); SA2(C): COMPARE THE NUMBER OF HYPOTENSIVE/HYPERTENSIVE EPISODES WITH VITRACK CONTINUOUS MEASUREMENTS VS. THE INTERMITTENT CUFF MEASUREMENTS. MILESTONE: VITRACK PROVIDES RELIABLE 24-HR DATA DESPITE PATIENT MOVEMENT. THE DATA GENERATED WILL VALIDATE VITRACK AS THE FIRST STANDALONE TECHNOLOGY FOR ACCURATE AND CONTINUOUS BP DURING PREGNANCY. THIS FOUNDATIONAL DATA WILL INFORM THE COMMERCIAL BUILD, FINAL CLINICAL VALIDATION AND FDA SUBMISSION, AND 510(K) APPROVAL FOR CONTINUOUS BP MEASUREMENT IN PREGNANT WOMEN. IN ADDITION, FURTHER RANDOMIZED CONTROL TRIALS WILL VALIDATE THE APPLICATION OF VITRACK IN RISK PREDICTION, EARLY DIAGNOSIS, AND MANAGEMENT OF PREECLAMPSIA AND, THUS, AS THE NEW STANDARD OF CARE FOR BP MONITORING DURING PREGNANCY.

ADVANCING HUMAN RIGHTS AND DEMOCRATIC VALUES

5/7 PSYCHIATRIC GENOMICS CONSORTIUM: FINDING ACTIONABLE VARIATION

CONTINUOUS NON-INVASIVE ASSESSMENT OF BLOOD PRESSURE PROFILE IN PERSONS WITH ALZHEIMER'S AND ITS RELATED DEMENTIAS - PROJECT SUMMARY THERE IS AN UNMET CLINICAL NEED FOR AN ACCURATE, STANDALONE, CONTINUOUS NON-INVASIVE BLOOD PRESSURE (CNIBP) MONITOR. CURRENT NON-INVASIVE, OCCLUSIVE ARM CUFF-BASED BP TECHNOLOGIES ARE INACCURATE AND PROVIDE ONLY SINGLE- POINT BP MEASUREMENTS. IN US HOSPITALS, THERE ARE CLOSE TO 44 MILLION IN-PATIENT ADMISSIONS AND SURGERIES PER YEAR THAT REQUIRE BP MONITORING, BUT PERIODIC CUFF-BASED MEASURES LEAD TO MONITORING GAPS AND POORER OUTCOMES, INCLUDING 300,000 PREVENTABLE CARDIAC ARRESTS PER YEAR. IN HOSPITALS, CONTINUOUS BP MONITORING CAN BE ACHIEVED WITH INVASIVE INTRA-ARTERIAL PRESSURE (IAP) MONITORING, BUT WITH SIGNIFICANT RISKS. APART FROM CRITICAL CARE AND OTHER HOSPITAL SETTINGS, CNIBP TECHNOLOGY HAS BROADER APPLICATION IN 103 MILLION AMERICANS WITH HYPERTENSION, A LEADING CAUSE OF STROKE AND HEART ATTACKS. INITIAL MARKET FOCUS FOR DYNOCARDIA IS TO DEVELOP STANDALONE CNIBP ALTERNATIVE TO IAP AND ARM CUFF-BASED DEVICES FOR USE IN INTENSIVE CARE UNITS AND OPERATING ROOMS. DYNOCARDIA’S VITRACK® IS THE FIRST STANDALONE, CUFF-LESS, WRIST WEARABLE DEVICE FOR CNIBP MONITORING. COMPARED TO OTHER CNIBP TECHNOLOGIES, THE ADVANTAGES OF VITRACK INCLUDE: (1) NEW METHOD FOR CONTINUOUS MEASUREMENT OF BP WITHOUT A CUFF: VITRACK USES SKIN FORCE/DISPLACEMENT INFORMATION TO PROVIDE A DIRECT, CONTINUOUS MEASUREMENT OF SYSTOLIC AND DIASTOLIC BP. THIS METHOD IS ANALOGOUS TO THE GOLD STANDARD AUSCULTATORY METHOD IN WHICH THE PHYSICIAN MEASURES SYSTOLIC AND DIASTOLIC BP DIRECTLY WITH AN ARM CUFF AND STETHOSCOPE (SOUND) AT A SINGLE TIME POINT, BUT VITRACK MEASURES CONTINUOUSLY; (2) ACCURACY: AT LEAST AS ACCURATE AS THE GOLD STANDARD (3) NOVEL TECHNOLOGY: FIRST-OF-ITS-KIND CUFF-LESS, WEARABLE TECHNOLOGY; (4) VERSATILITY: ALSO MEASURES RESPIRATORY, HEART RATE OTHER HEMODYNAMIC PARAMETERS; AND (5) EASE OF USE: UTILIZES A CAMERA-BASED OPTOMECHANICAL SENSOR THAT CAN LOCK PULSATION AUTOMATICALLY WITHOUT NEED FOR PRECISE PLACEMENT. IN SBIR PHASE 1-LIKE PRECLINICAL STUDIES, USING THE FULLY AUTOMATED LAB PROTOTYPE, IN LARGE AND SMALL ANIMAL STUDIES, VITRACK CORRELATED ONE-TO ONE (R2= 0.96) WITH INVASIVE IAP. IN CLINICAL STUDIES OF 80 OUTPATIENTS OVER A WIDE RANGE OF BPS, VITRACK MET FDA EQUIVALENCY STANDARDS FOR MEASURING BP AND IN FURTHER OUTPATIENT STUDIES, CONTINUOUSLY MEASURED BEAT-TO-BEAT BP RELIABLY, DEMONSTRATING ITS FEASIBILITY AS A STANDALONE CNIBP MONITOR. THE GOAL OF THIS DIRECT TO PHASE II PROPOSAL IS TO REFINE THE CURRENT PROTOTYPE TO BUILD CLINICAL STUDY DEVICES AS PER ISO13485 DESIGN CONTROLS AND THEN ASSESS CLINICAL PERFORMANCE IN HUMAN SUBJECTS TO PRODUCE AN OPTIMIZED COMMERCIALLY VIABLE VITRACK DEVICE FOR USE IN CRITICAL CARE SETTINGS. THE OUTCOME OF THIS STUDY WILL ESTABLISH VITRACK AS THE FIRST STANDALONE, WEARABLE CNIBP ALTERNATE TO IAP AND ENABLE NEXT PHASE FUNDING TO BUILD THE PRODUCTION EQUIVALENT VITRACK WRIST DEVICES, AS A PRELUDE TO FINAL CLINICAL VALIDATION AND FDA 510(K) CLEARANCE.

PERSONAL RESPONSIBILITY EDUCATION PROGRAM (PREP) COMPETITIVE GRANTS UNDER THE AFFORDABLE CARE ACT (ACA)

DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME - ABSTRACT STARLIGHT CARDIOVASCULAR IS DEVELOPING WHAT WILL BE THE FIRST FDA APPROVED PERCUTANEOUS FLOW RESTRICTOR TO REPLACE SURGICAL BANDING IN CONGENITAL HEART DISEASE (CHD). MANY BABIES WITH CHDS SUCH AS HYPOPLASTIC LEFT HEART SYNDROME AND COMMUNICATING HEART DEFECTS HAVE OVERCIRCULATION TO THE LOWER-RESISTANCE PULMONARY BED AND UNDERCIRCULATION TO THE REST OF THE BODY. REDUCING PULMONARY ARTERY FLOW IN THESE BABIES CREATES A MORE PHYSIOLOGIC BALANCE BETWEEN PULMONARY AND SYSTEMIC CIRCULATIONS AND ALLOWS THEM TO SURVIVE THE FIRST FEW WEEKS OF LIFE, REDUCES DAMAGE TO THEIR PULMONARY ARTERIES, AND ENABLES THEM TO GROW LARGER AND STRONGER PRIOR TO THEIR NEXT, MORE INVASIVE SURGERY TO REPAIR THEIR HEART DEFECT. CURRENTLY, THE REDUCTION OF PULMONARY BLOOD FLOW IN THESE NEONATAL PATIENTS IS ACHIEVED BY SURGICAL PULMONARY ARTERY BANDING, BUT BANDING REQUIRES AN OPEN-CHEST SURGERY AND CAN INTERFERE WITH PULMONARY ARTERY GROWTH, THUS LIMITING ITS CLINICAL UTILITY. A PERCUTANEOUS SOLUTION COULD ELIMINATE AN OPEN CHEST SURGERY FOR A NEWBORN. PEDIATRIC INTERVENTIONAL CARDIOLOGISTS HAVE SO MUCH INTEREST IN OVERCOMING THE NEGATIVE EFFECTS OF BANDING THAT THEY ARE PERFORATING VASCULAR PLUGS TO CREATE HAND-MADE PERCUTANEOUS PULMONARY FLOW RESTRICTORS, AND EARLY CLINICAL USE OF THESE DEVICES HAVE PRODUCED PROMISING RESULTS. HOWEVER, USE OF THESE MODIFIED VASCULAR PLUGS IS LIMITED BY TECHNICAL CHALLENGES SUCH AS LONG IMPLANT LENGTHS, DEVICE MIGRATION, AND LACK OF ADJUSTABILITY AND RELIABILITY. ADDITIONALLY, MANY CLINICIANS ARE UNCOMFORTABLE WITH MODIFYING AN OCCLUDER BY HAND AND USING IT OFF-LABEL. STARLIGHT CARDIOVASCULAR IS DEVELOPING A CATHETER-DELIVERED, PERCUTANEOUS, AND ADJUSTABLE BRANCH PULMONARY ARTERY BLOOD FLOW RESTRICTOR TO REPLACE SURGICAL BANDING. OUR DEVICE ADDRESSES THE SHORTCOMINGS FROM PREVIOUS ATTEMPTS AT A PERCUTANEOUS FLOW RESTRICTOR BY PROVIDING RELIABLE FLOW REDUCTION, PERCUTANEOUS ADJUSTABILITY, AND A SHORT AND WELL-ANCHORED IMPLANT DESIGN THAT IS REMOVABLE. THESE PULMONARY FLOW RESTRICTORS COULD BENEFIT AS MANY AS 130,000 BABIES BORN EACH YEAR WITH CHDS INCLUDING HYPOPLASTIC LEFT HEART SYNDROME, VENTRICULAR SEPTAL DEFECTS, AND TRUNCUS ARTERIOSUS. THIS PHASE II SBIR GRANT WILL CONSIST OF DEVICE DESIGN OPTIMIZATION THROUGH DESIGN ITERATION, BENCHTOP TESTING, END-USER SIMULATED USE TESTING BY PEDIATRIC INTERVENTIONAL CARDIOLOGISTS, AND ACUTE AND CHRONIC ANIMAL STUDIES. SUCCESSFUL COMPLETION OF THIS PROJECT WILL PRODUCE A FINAL DEVICE DESIGN THAT IS READY FOR FORMAL VERIFICATION AND VALIDATION TESTING, CLINICAL STUDIES, FDA APPROVAL, AND COMMERCIALIZATION.

AMERICAN RESCUE PLAN

THE AWARD WITH THE INTERNATIONAL CENTER FOR AGRICULTURAL RESEARCH IN DRY AREAS (ICARDA) WILL WORK COLLABORATIVELY WITH THE USDA FOREIGN AGRICULTURAL SERVICE TO IMPROVE FERTILIZER USE EFFICIENCY THROUGHOUT THE AGRICULTURAL REGIONS OF PAKISTAN. THIS WILL INVOLVE WORKING WITH FARMERS, EXTENSIONISTS, MINISTRY OFFICIALS, RESEARCHERS, AND UNIVERSITIES, ALONG WITH OTHERS TO PROVIDE TRAINING ON FERTILIZER USE EFFICIENCY. THROUGH EXPANDING KNOWLEDGE ON FERTILIZER USE EFFICIENCY, THE WORK CARRIED OUT IN THIS PROJECT IS EXPECTED TO REDUCE GREENHOUSE GAS EMISSIONS FROM FERTILIZER USE. SUB AWARDS ARE ANTICIPATED FOR THIS AGREEMENT TO FACILITATE COLLABORATION WITH UNIVERSITY PARTNERS AND RESEARCH INSTITUTIONS TO PROVIDE TECHNICAL EXPERTISE TO PROJECT DEVELOPMENT AND TRAINING.

A NOVEL POLYMERIC VALVE FOR TRANSCATHETER AORTIC VALVE REPLACEMENT

HEAD START AND EARLY HEAD START

PEDIATRIC IMPLANTABLE LOW-SHEAR PULSATILE BLOOD PUMP WITH PHYSIOLOGIC SENSING AND CONTROL

TEACHING AT THE RIGHT LEVEL ACTIVITY

IMPROVING CARDIAC QUALITY, PATIENT EXPERIENCE AND COST

HEPTAX FOR ALCOHOLIC LIVER DISEASE

ENGAGES PERSONS 55 AND OLDER IN SUPPORTIVE SERVICE TO CHILDREN IN NEED

UNIVERSITY OF MONTREAL CARDIAC SURGERY CLINICAL INVESTIGATION GROUP

FOSTER GRANDPARENT PROGRAM

UNIVERSITY OF MONTREAL CARDIAC SURGERY CLINICAL INVESTIGATION GROUP

PEER EDUCATION TRAINING SITES AND RESOURCE AND EVALUATION CENTER

ENGAGES PERSONS 55 AND OLDER IN VOLUNTEER SERVICE IN THEIR COMMUNITIES

SBIR PHASE II: DEVELOPMENT OF MOTION ARTIFACT CORRECTION SYSTEMS FOR VITRACK: AN ACCURATE, CONTINUOUS, AND NON-INVASIVE BLOOD PRESSURE MONITOR -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS TO MEET THE URGENT NEED FOR A WEARABLE BLOOD PRESSURE (BP) MONITOR FOR ACCURATE AND CONTINUOUS BP MEASUREMENTS. THE CURRENT STANDARD FOR ARM CUFF-BASED BP ASSESSMENTS IS UNRELIABLE AND LIMITED TO SINGLE TIME-POINT BP ESTIMATES, BUT AN INDIVIDUAL?S BP FLUCTUATES SIGNIFICANTLY OVER 24 HOURS. IN US HOSPITALS, 35 MILLION PATIENTS ARE ADMITTED ANNUALLY FOR CRITICAL ILLNESS AND/OR UNDERGO MAJOR SURGERIES THAT REQUIRE BP MONITORING. INACCURATE, SINGLE-POINT, CUFF-BASED BP MONITORING DURING SURGERY LEADS TO UNRECOGNIZED LOW BP AND CONTRIBUTES TO 14 MILLION HEART ATTACKS AND KIDNEY FAILURES ANNUALLY. VITRACK IS A WRIST-WEARABLE DEVICE THAT UTILIZES A PROPRIETARY OPTOMECHANICAL SENSOR ARRAY AND COMPUTER VISION TO ACCURATELY AND CONTINUOUSLY MEASURE RADIAL ARTERY BP WITHOUT REQUIRING EXTERNAL CALIBRATION. HOWEVER, CONTINUOUSLY MEASURING BP IN CLINICAL SETTINGS IS CHALLENGING DUE TO ARTIFACTS FROM PATIENT MOVEMENTS. IN NSF PHASE 1, VITRACK'S SENSOR ARRAY WAS USED TO DEVELOP AN ADVANCED COMPUTER VISION TECHNOLOGY FOR MOTION ARTIFACT CORRECTION. OTHER THAN THE HOSPITAL MARKET, THE MULTI-BILLION DOLLAR MARKET SEGMENTS FOR AN ACCURATE AND CONTINUOUS BP MONITOR INCLUDE REMOTE PATIENT MONITORING FOR 104 MILLION AMERICANS WITH HIGH BP AND THE CONSUMER WELLNESS MARKETS. THE OBJECTIVE OF THIS SMALL BUSINESS INNOVATION RESEARCH PHASE II PROJECT IS TO IMPROVE COMPUTER VISION TECHNOLOGY FOR MOTION CORRECTION AND MAKE IT SUITABLE FOR USE IN VARIOUS HOSPITAL SETTINGS WITH DIFFERENT TYPES OF MOTION ARTIFACTS. THE PROJECT WILL BEGIN BY IMPROVING THE EFFECTIVENESS AND ADAPTABILITY OF COMPUTER VISION-BASED ALGORITHMS THROUGH TESTING AND OPTIMIZATION USING A WIDE RANGE OF PATIENT DATA. ARTIFICIAL INTELLIGENCE (AI) WILL THEN BE INTEGRATED TO FURTHER IMPROVE THE ALGORITHMS' ABILITY TO HANDLE VARIOUS MOTION ARTIFACTS. IN ORDER TO ACHIEVE THIS GOAL, WE WILL CREATE THOUSANDS OF SYNTHETIC 3D-RENDERED VIDEOS USING VARIOUS COMBINATIONS OF REAL-WORLD VITRACK DATA, BOTH WITH AND WITHOUT MOTION ARTIFACTS. THESE VIDEOS WILL THEN BE UTILIZED TO TRAIN A SPECIFIC TYPE OF AI ALGORITHM KNOWN AS A DEEP NEURAL NETWORK, USING A MODERN APPROACH CALLED A VISION TRANSFORMER. THE MAIN OBJECTIVE OF THIS TRAINING IS TO ENABLE THE ALGORITHM TO RECOGNIZE AND ADDRESS MOTION ARTIFACTS WITHOUT COMPROMISING THE PHYSIOLOGICAL SIGNAL. AFTER DEVELOPING, WE WILL TEST THE ALGORITHMS' ACCURACY IN PROVIDING CONTINUOUS BP READINGS ACROSS A VARIETY OF CLINICAL DATA. ONCE VALIDATED, THE ALGORITHMS WILL BE INTEGRATED INTO THE VITRACK DEVICE THROUGH A SOFTWARE MODULE FOLLOWING FDA GUIDELINES FOR GOOD MACHINE LEARNING PRACTICES. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

MINIATURIZATION OF THE LOW-SHEAR PULSATILE TORVAD FOR PEDIATRIC HEART FAILURE

SUDDEN CARDIAC DEATH IN HEART FAILURE TRIAL 10 YEAR FOLLOW-UP (SCD-HEFT 10 YR.)

HEALTH CARE AND OTHER FACILITIES

DURABLE MUSCLE-PROSTHETIC BOND FOR ARTIFICIAL TENDONS

COVID RELIEF FOR BIOFUEL PRODUCERS GRANTS

STTR PHASE II: DEVELOPMENT AND COMMERCIALIZATION OF A WEARABLE LONG-TERM MONITOR FOR CARDIAC ARRHYTHMIAS

FY10 MINORITY COMMUNITY HIV/AIDS PARTNERSHIP: PREVENTING RISKY BEHAVIORS AMONG MINORITY COLLEGE STUDENTS

SYNCHRONOUS VALVELESS PULSATILE SUPPORT DEVICE FOR THE FAILING HEART

AN ESTIMATED 75 FOSTER GRANDPARENTS (FGS) WILL PARTICIPATE IN ST. LOUIS FOSTER GRANDPARENT PROGRAM MANAGED BY CARDINAL RITTER SENIOR SERVICES (CRSS). OF THESE, 72 FG VOLUNTEERS WILL BE PLACED IN OUTCOME PRODUCING ASSIGNMENTS SERVING CHILDREN FROM SOCIOECONOMICALLY DISADVANTAGED FAMILIES WHO EXPERIENCE SOCIAL/EMOTIONAL OR EDUCATIONAL CHALLENGES AND TAKE PART IN CNCS-SUPPORTED EARLY CHILDHOOD EDUCATION PROGRAMS. UNDER THE DIRECTION OF CLASSROOM TEACHERS, VOLUNTEERS WILL PROVIDE DIRECT SERVICE TO STUDENTS WHO HAVE DEMONSTRATED SPECIAL OR EXCEPTIONAL NEEDS. FGP VOLUNTEERS WILL SERVE AT 24 VOLUNTEER STATIONS LOCATED THROUGHOUT THE CITY OF ST. LOUIS AND ST. LOUIS COUNTY. VOLUNTEER STATIONS INCLUDE HEAD START AND COMMUNITY EARLY CHILDHOOD EDUCATION PROGRAMS SERVING PRESCHOOL-AGED CHILDREN. THE PRIMARY FOCUS AREA OF THIS PROJECT IS EDUCATION, WITHIN THE OBJECTIVE OF SCHOOL READINESS. AT THE END OF THE GRANT PERIOD, 200 PRESCHOOL STUDENTS SERVED AT THESE 24 VOLUNTEER STATIONS WILL SHOW GAINS IN SCHOOL READINESS AFTER RECEIVING SOCIAL AND EMOTIONAL SUPPORT FROM FG VOLUNTEERS. AN ADDITIONAL THREE FGP VOLUNTEERS WILL SERVE CHILDREN 0-5 YEARS OF AGE FROM SOCIOECONOMICALLY DISADVANTAGED FAMILIES WHO PARTICIPATE IN THE TRANSITIONAL HOUSING CHILDCARE PROGRAM AT ST. LOUIS CRISIS NURSERY. THE ST. LOUIS CRISIS NURSERY PROVIDES A SAFE HAVEN FOR CHILDREN WHO REQUIRE TEMPORARY HOUSING AWAY FROM THEIR PRIMARY HOME AND FAMILY DUE TO AN EMERGENCY SITUATION. THE PRIMARY FOCUS AREA OF THIS PROJECT IS EDUCATION, WITHIN THE OBJECTIVE OF SCHOOL READINESS. AT THE END OF THE GRANT PERIOD, 20 PRESCHOOL-AGED STUDENTS SERVED AT THIS VOLUNTEER STATION WILL SHOW GAINS IN SCHOOL READINESS AFTER RECEIVING SOCIAL AND EMOTIONAL SUPPORT FROM THE FG VOLUNTEERS. THE ST. LOUIS FOSTER GRANDPARENT PROGRAM ANTICIPATES FEDERAL FUNDING IN THE AMOUNT OF $342,433 AND WILL PROVIDE NON-FEDERAL FUNDING ESTIMATED AT $126,344.

COMPREHENSIVE MR IMAGING OF ELDERLY VASCULAR FUNCTION: PHASE II

PURPOSE: TO PROMOTE ECONOMIC REVITALIZATION AND COMMUNITY DEVELOPMENT THROUGH INVESTMENT IN AND FINANCIAL ASSISTANCE TO COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS). PLANNED ACTIVITIES: FINANCIAL ASSISTANCE MUST BE USED FOR FINANCIAL PRODUCTS, FINANCIAL SERVICES (REGULATED INSTITUTIONS ONLY), DEVELOPMENT SERVICES, LOAN LOSS RESERVES, AND CAPITAL RESERVES (REGULATED INSTITUTIONS ONLY), IN AN ELIGIBLE MARKET OR THE RECIPIENT’S APPROVED TARGET MARKET. END GOALS: THE GOAL OF THE FINANCIAL ASSISTANCE IS FOR CDFIS TO BUILD THEIR FINANCIAL CAPACITY TO LEND TO ELIGIBLE MARKETS AND/OR THEIR TARGET MARKETS, IN ORDER TO SERVE RURAL AND URBAN LOW INCOME PEOPLE, AND COMMUNITIES ACROSS THE NATION THAT LACK ADEQUATE ACCESS TO AFFORDABLE FINANCIAL PRODUCTS AND FINANCIAL SERVICES. BENEFICIARIES: PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, OTHER PRIVATE INSTITUTION/ORGANIZATION INVESTMENT AREAS AND TARGETED POPULATIONS, AS DEFINED IN 12 C.F.R. 1805. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: SPECIFIC ACTIVITIES RELATING TO BROADBAND USAGE ARE NOT KNOWN AT THE TIME OF AWARD. REASON/PURPOSE OF MODIFICATION: THE RIEGLE ACT (P.L. 103 325), THE STATUTE WHICH AUTHORIZES THE CDFI PROGRAM, REQUIRES THAT FINANCIAL ASSISTANCE AWARDS, INCLUDING BASE FINANCIAL ASSISTANCE (BASE FA), DISABILITY FUNDS FINANCIAL ASSISTANCE (DF FA), AND PERSISTENT POVERTY COUNTIES FINANCIAL ASSISTANCE (PPC FA), BE MATCHED WITH FUNDS FROM NON FEDERAL GOVERNMENT SOURCES AND COMPARABLE IN FORM AND VALUE TO THE FA AWARD. MODIFICATIONS WOULD BE REQUIRED IF THERE IS A CHANGE IN THE FORM AND/OR AMOUNT ORIGINALLY OBLIGATED FOR THE AWARD, BASED ON APPROVED MATCHING FUNDS. NOTE: MATCHING FUNDS ARE REQUIRED ONLY FOR ORGANIZATIONS APPLYING AS CATEGORY II/CORE FA APPLICANTS UNDER THE CDFI PROGRAM. MATCHING FUNDS ARE NOT REQUIRED FOR ANY NATIVE CDFI APPLICANTS OR HOUSING PRODUCTION FINANCIAL ASSISTANCE AWARDS (HP FA). ADDITIONALLY, MATCHING FUNDS ARE NOT REQUIRED FOR SMALL AND EMERGING CDFI ASSISTANCE (SECA) FA APPLICANTS AND HEALTHY FOOD FINANCING INITIATIVES (HFFI) FA APPLICANTS, PENDING FINAL FY 2025 APPROPRIATIONS LANGUAGE.

FOSTER GRANDPARENT PROGRAM

CANADA EAST AND WEST NETWORK

ELEMENTARY AND SECONDARY SCHOOL COUNSELING

WASTE DISPOSAL GRANTS - REGULAR

SPC TENANT BASED RA

SPC TENANT BASED RA

5/5 INTERNATIONAL CONSORTIUM ON BRAIN AND BEHAVIOR IN 22Q11.2 DELETION SYNDROME

SPC TENANT BASED RA

DISTANCE LEARNING GRANT

ASSISTANCE TO FIREFIGHTERS GRANTS

REGION IX STD-RELATED REPRODUCTIVE HEALTH PREVENTION TRAINING AND TECHNICAL ASSISTANCE CENTER

PART B - CDC STD-RELATED REPRODUCTIVE HEALTH, PREVENTION, TRAINING, AND TECHNICAL ASSISTANCE CENTER - 2

CONTINUUM OF CARE PROGRAM

MULTIFAMILY HOUSING SERVICE COORDINATORS

METHODS TO MEASURE, PREDICT, AND RELATE FRICTION, WEAR ,AND FUEL ECONOMY

PURPOSE: TO PROMOTE ECONOMIC REVITALIZATION AND COMMUNITY DEVELOPMENT THROUGH INVESTMENT IN AND FINANCIAL ASSISTANCE TO COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS). PLANNED ACTIVITIES: FINANCIAL ASSISTANCE MUST BE USED FOR FINANCIAL PRODUCTS, FINANCIAL SERVICES (REGULATED INSTITUTIONS ONLY), DEVELOPMENT SERVICES, LOAN LOSS RESERVES, AND CAPITAL RESERVES (REGULATED INSTITUTIONS ONLY), IN AN ELIGIBLE MARKET OR THE RECIPIENT’S APPROVED TARGET MARKET. END GOALS: THE GOAL OF THE FINANCIAL ASSISTANCE IS FOR CDFIS TO BUILD THEIR FINANCIAL CAPACITY TO LEND TO ELIGIBLE MARKETS AND/OR THEIR TARGET MARKETS, IN ORDER TO SERVE RURAL AND URBAN LOW INCOME PEOPLE, AND COMMUNITIES ACROSS THE NATION THAT LACK ADEQUATE ACCESS TO AFFORDABLE FINANCIAL PRODUCTS AND FINANCIAL SERVICES. BENEFICIARIES: PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, OTHER PRIVATE INSTITUTION/ORGANIZATION INVESTMENT AREAS AND TARGETED POPULATIONS, AS DEFINED IN 12 C.F.R. 1805. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: SPECIFIC ACTIVITIES RELATING TO BROADBAND USAGE ARE NOT KNOWN AT THE TIME OF AWARD. REASON/PURPOSE OF MODIFICATION: THE RIEGLE ACT (P.L. 103 325), THE STATUTE WHICH AUTHORIZES THE CDFI PROGRAM, REQUIRES THAT FINANCIAL ASSISTANCE AWARDS, INCLUDING BASE FINANCIAL ASSISTANCE (BASE FA), DISABILITY FUNDS FINANCIAL ASSISTANCE (DF FA), AND PERSISTENT POVERTY COUNTIES FINANCIAL ASSISTANCE (PPC FA), BE MATCHED WITH FUNDS FROM NON FEDERAL GOVERNMENT SOURCES AND COMPARABLE IN FORM AND VALUE TO THE FA AWARD. MODIFICATIONS WOULD BE REQUIRED IF THERE IS A CHANGE IN THE FORM AND/OR AMOUNT ORIGINALLY OBLIGATED FOR THE AWARD, BASED ON APPROVED MATCHING FUNDS. NOTE: MATCHING FUNDS ARE REQUIRED ONLY FOR ORGANIZATIONS APPLYING AS CATEGORY II/CORE FA APPLICANTS UNDER THE CDFI PROGRAM. MATCHING FUNDS ARE NOT REQUIRED FOR ANY NATIVE CDFI APPLICANTS OR HOUSING PRODUCTION FINANCIAL ASSISTANCE AWARDS (HP FA). ADDITIONALLY, MATCHING FUNDS ARE NOT REQUIRED FOR SMALL AND EMERGING CDFI ASSISTANCE (SECA) FA APPLICANTS AND HEALTHY FOOD FINANCING INITIATIVES (HFFI) FA APPLICANTS, PENDING FINAL FY 2025 APPROPRIATIONS LANGUAGE.

THIS AWARD FUNDS THE APPROVED 2022-23 FGP PROGRAM. YOUR 2022-23 STATUTORY MATCH IS 10% AND YOUR BUDGETARY MATCH IS 10.0%. THIS AWARD BEGINS THE FIRST YEAR OF YOUR PROPOSED PROJECT PERIOD OF PERFORMANCE. THIS AWARD ACTION ADDS PERMANENT FUNDING TO INCREASE THE STIPEND AMOUNT FROM $3.00 TO $3.15 PER HOUR AND ALSO INCLUDES A PERMANENT ADMINISTRATIVE INCREASE OF $10,990. THESE FUNDING AUGMENTATIONS CHANGES THE TOTAL FEDERAL FUNDING AMOUNT TO $401,950.

BUILDING THE CAPACITY OF AGRICULTURAL SERVICE PROVIDERS TO ENHANCE ADOPTION OF TECHNOLOGIES AND BEST MANAGEMENT PRACTICES FOR IMPROVING WATER USE-EFFICIENCY AND SOIL FERTILITY AND HEALTH

AUTOCRINE WNT SIGNALING IN HUMAN BREAST AND OVARIAN CANCER CELLS

COMMERCIALIZATION READINESS FOR DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY - ABSTRACT THE TECHNICAL CHALLENGES FACED BY PEDIATRIC CARDIOVASCULAR PHYSICIANS (SURGEONS AND INTERVENTIONALISTS ALIKE) HAVE LONG BEEN IGNORED, FORCING THEM TO USE DEVICES DESIGNED FOR ADULTS AND DIFFERENT CONDITIONS TO TREAT AILING BABIES WITH VERY SPECIFIC ANATOMICAL CONSIDERATIONS. ONE SUCH CASE IS IN THE SUSTAINED OPENING OF THE DUCTUS ARTERIOSUS, A NATURAL CONDUIT THAT EXISTS IN ALL NEWBORNS BUT CLOSES SHORTLY AFTER BIRTH. IN CERTAIN CONGENITAL HEART DEFECTS, IT IS CRUCIAL TO MAINTAIN DUCTUS PATENCY FOR THE NEWBORN TO SURVIVE WITHOUT SURGICAL INTERVENTION. THERE IS NO DUCTUS ARTERIOSUS STENT COMMERCIALLY AVAILABLE IN THE US. PEDIATRIC INTERVENTIONAL CARDIOLOGISTS CURRENTLY REPURPOSE ADULT STENTS FOR THE DUCTUS, AND ALL-CAUSE DUCTUS REINTERVENTION IS 47%. THE ALTERNATIVE IS OPEN-CHEST SURGERY ON A NEONATE TO PLACE A SHUNT THAT CARRIES A 13% RISK OF MORBIDITY AND 7% RISK OF MORTALITY, EVEN IN THE UNITED STATES. STARLIGHT CARDIOVASCULAR HAS CREATED A DUCTUS ARTERIOSUS STENT THAT IS SPECIFICALLY DESIGNED TO ADDRESS THE CHALLENGES FACING TREATING PHYSICIANS, INCLUDING A RIGHT-SIZED DELIVERY SYSTEM, END-TO-END COVERAGE OF THE DUCTUS, NAVIGATION AND DEPLOYMENT THROUGH TORTUOUS DUCTUS ANATOMY, AND PRECISE PLACEMENT TO AVOID STENT PROTRUSION INTO THE AORTA AND PULMONARY ARTERIES. A STENT DESIGNED AND TESTED SPECIFICALLY FOR THIS PURPOSE HAS THE POTENTIAL TO DECREASE REINTERVENTIONS, MORBIDITY, AND POTENTIALLY MORTALITY FOR BABIES WITH DUCTAL- DEPENDENT CIRCULATION. THE FEASIBILITY OF THE INNOVATIVE STENT SYSTEM DESIGNED FOR PEDIATRIC APPLICATIONS USING SELF-EXPANDING TECHNOLOGY HAS BEEN DEMONSTRATED, AND A PHASE II SBIR IS UNDERWAY TO COMPLETE THE FORMAL PRECLINICAL TESTING OF THE DEVICE. THIS CRP SBIR APPLICATION PROPOSES FINALIZING THE MANUFACTURING PROCESSES, MANUFACTURING DEVICES FOR CLINICAL USE, AND OBTAINING INVESTIGATIONAL DEVICE EXEMPTION (IDE) APPROVAL FROM FDA TO BEGIN A CLINICAL TRIAL. THIS CRP PROJECT WILL ENABLE STARLIGHT TO MOVE INTO CLINICAL TESTING FOR ITS DUCTUS ARTERIOSUS STENT SYSTEM. IF THE TRIAL IS SUCCESSFUL, STARLIGHT CARDIOVASCULAR WILL SEEK FDA APPROVAL AND COMMERCIALIZATION OF THE FIRST DUCTUS ARTERIOSUS STENT IN THE UNITED STATES.

PURPOSE: TO PROVIDE GRANTS TO COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS) FOR THE FOLLOWING PURPOSES 1) TO EXPAND LENDING, GRANT MAKING AND INVESTMENT ACTIVITIES IN LOW OR MODERATE INCOME COMMUNITIES AND TO BORROWERS THAT HAVE HISTORICALLY EXPERIENCED SIGNIFICANT UNMET CAPITAL AND FINANCIAL SERVICES NEEDS AND WERE DISPROPORTIONATELY IMPACTED BY THE COVID 19 PANDEMIC; AND 2) TO ENABLE CDFIS TO BUILD ORGANIZATIONAL CAPACITY AND ACQUIRE TECHNOLOGY, STAFF, AND OTHER TOOLS NECESSARY TO ACCOMPLISH THE ACTIVITIES UNDER A CDFI ERP AWARD. PLANNED ACTIVITIES: ELIGIBLE ACTIVITIES INCLUDE FINANCIAL PRODUCTS, FINANCIAL SERVICES, DEVELOPMENT SERVICES, GRANTS, LOAN LOSS RESERVES AND CAPITAL RESERVES THAT MAY BE USED TO MITIGATE THE IMPACT OF THE COVID 19 PANDEMIC ON UNEMPLOYMENT, CHILDCARE, HEALTHCARE, MENTAL HEALTHCARE, AFFORDABLE HOUSING, AFFORDABLE HOUSING FINANCE, SMALL BUSINESS, SMALL FARMS, BROADBAND INTERNET, AND FOOD SUFFICIENCY. IN ADDITION, TO SUPPORT CDFIS IN BUILDING THEIR CAPACITY TO RESPOND TO THE ECONOMIC IMPACT OF COVID 19, CDFI ERP AWARDS MAY BE USED FOR COMPENSATION PERSONAL SERVICES; COMPENSATION FRINGE BENEFITS; PROFESSIONAL SERVICE COSTS; TRAVEL COSTS; TRAINING AND EDUCATION COSTS; EQUIPMENT; SUPPLIES. END GOALS: EXPANDED FINANCING FOR LOW TO MODERATE INCOME COMMUNITIES AND INDIVIDUALS THAT HAVE HISTORICALLY EXPERIENCED SIGNIFICANT UNMET CAPITAL AND FINANCIAL SERVICES NEEDS AND WERE DISPROPORTIONATELY IMPACTED BY THE COVID 19 PANDEMIC INCLUDING SPECIFIC DESIGNATED COVID IMPACTED CDFI ERP ELIGIBLE GEOGRAPHIES AS AREAS THAT MAY BENEFIT FROM CDFI ERP ASSISTANCE. BENEFICIARIES: CERTIFIED CDFIS WHICH MAY BE FOR PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, AND OTHER PRIVATE INSTITUTION/ORGANIZATION, AS DEFINED IN 12 C.F.R. 1805, AND LOW AND MODERATE INCOME INDIVIDUALS AND FAMILIES. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: SPECIFIC ACTIVITIES RELATING TO BROADBAND USAGE ARE NOT KNOWN AT THE TIME OF AWARD. REASON/PURPOSE OF MODIFICATION: NOT APPLICABLE.

DESIGN VERIFICATION AND VALIDATION OF VITRACK - AN ACCURATE, CONTINUOUS, NON-INVASIVE BLOOD PRESSURE MONITOR - PROJECT SUMMARY CURRENT NON-INVASIVE BLOOD PRESSURE (BP) TECHNOLOGIES ARE OCCLUSIVE ARM CUFF-BASED AND PROVIDE ONLY SINGLE- POINT BP MEASUREMENTS. IN US HOSPITALS, 35 MILLION CRITICALLY ILL PATIENTS ANNUALLY REQUIRE BP MONITORING. STILL, PERIODIC CUFF-BASED MEASURES LEAD TO MONITORING GAPS AND COMPLICATIONS, INCLUDING 14 MILLION EPISODES OF ACUTE KIDNEY INJURY AND MYOCARDIAL INJURY ANNUALLY. IN HOSPITALS, CONTINUOUS BP MONITORING CAN BE ACHIEVED WITH INVASIVE INTRA-ARTERIAL PRESSURE (IAP) MONITORING, BUT WITH SIGNIFICANT RISKS. TO ADDRESS THESE LIMITATIONS, DYNOCARDIA HAS DEVELOPED VITRACK, A CONTINUOUS NONINVASIVE BP (CNIBP). VITRACK IS A CUFF-LESS, WRIST-WEARABLE DEVICE WITH A PROPRIETARY OPTOMECHANICAL SENSOR AND COMPUTER VISION TECHNOLOGY FOR ACCURATE AND CONTINUOUS BP, HEART, AND ADVANCED HEMODYNAMIC PARAMETERS. VITRACK IS THE FIRST TO MEASURE BEAT-TO-BEAT SYSTOLIC (SBP) AND DIASTOLIC (DBP) BPS DIRECTLY WITHOUT EXTERNAL CALIBRATION, IRRESPECTIVE OF SUBJECT MOVEMENT OR WRIST POSITION RELATIVE TO THE HEART (HYDROSTATIC PRESSURE CHANGE). IN THE SBIR PHASE II STUDY [1 R44 HL158374], WE ACHIEVED THE PROPOSED MILESTONES: (A) IMPROVED THE CORE VITRACK TECHNOLOGIES AND BUILT MINIMAL VIABLE PRODUCT (MVP); AND (B) CLINICAL TESTING OF MVP AGAINST IAP IN 60 PATIENTS, DEMONSTRATED ACCURATE AND CONTINUOUS WAVEFORM AND BP READINGS EVERY 20 SECONDS (Q20) REGARDLESS OF MOVEMENT, DIVERGENT BPS, ABNORMAL HEART RHYTHMS, AND HEMODYNAMIC CONDITIONS. SUBSEQUENTLY, WE HAVE ACHIEVED SEVERAL MILESTONES, INCLUDING THE SUCCESSFUL DEPLOYMENT OF THE MVP IN SEVERAL RENOWNED HOSPITALS TO DEMONSTRATE ITS EFFECTIVENESS AND GATHER USER FEEDBACK. BASED ON THE USER FEEDBACK, WE HAVE COMPLETED THE FINAL PRODUCT REQUIREMENTS AND FORM FACTOR AND BEGUN DEVELOPING THE PRODUCTION EQUIVALENT DEVICE IN ACCORDANCE WITH DESIGN CONTROLS. WITH THE SUPPORT OF THE CRP PROGRAM, WE WILL COMPLETE THE VERIFICATION AND VALIDATION (V&V) OF THE PRODUCTION-GRADE VITRACK HOSPITAL DEVICE. THIS WILL HELP TO MITIGATE RISKS AND ENABLE US TO SUBMIT THE FDA 510K CLEARANCE. THE VITRACK WEARABLE WILL IMPROVE OUTCOMES IN CRITICALLY ILL HOSPITAL PATIENTS, LEADING TO ~$14 B IN ANNUAL SAVINGS IN HEALTHCARE COSTS. THE INITIAL MARKET VALIDATION IN HOSPITALS WILL FACILITATE EXPANSION INTO OTHER MARKETS, SUCH AS REMOTE PATIENT MONITORING, CHRONIC DISEASE MANAGEMENT, AND CONSUMER WELLNESS.

REDUCING AUTOMOTIVE CAPEX BARRIERS THROUGH DESIGN, MANUFACTURING AND MATERIALS

EDI SPECIAL PROJECTS

DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY - ABSTRACT THE TECHNICAL CHALLENGES FACED BY PEDIATRIC CARDIOVASCULAR PHYSICIANS (SURGEONS AND INTERVENTIONALISTS ALIKE) HAVE LONG BEEN IGNORED, FORCING THEM TO USE DEVICES DESIGNED FOR ADULTS AND DIFFERENT CONDITIONS TO TREAT AILING BABIES WITH VERY SPECIFIC ANATOMICAL CONSIDERATIONS. ONE SUCH CASE IS IN THE SUSTAINED OPENING OF THE DUCTUS ARTERIOSUS, A NATURAL CONDUIT THAT EXISTS IN ALL NEWBORNS BUT CLOSES SHORTLY AFTER BIRTH. IN CERTAIN CONGENITAL HEART DEFECTS, IT IS CRUCIAL TO MAINTAIN DUCTUS PATENCY FOR THE NEWBORN TO SURVIVE WITHOUT SURGICAL INTERVENTION. THERE IS NO DUCTUS ARTERIOSUS STENT COMMERCIALLY AVAILABLE IN THE US. PEDIATRIC INTERVENTIONAL CARDIOLOGISTS CURRENTLY REPURPOSE ADULT CORONARY ARTERY STENTS FOR THE DUCTUS, AND ALL-CAUSE DUCTUS REINTERVENTION IS 47%. THE ALTERNATIVE IS SURGERY ON A NEONATE TO PLACE A SHUNT THAT CARRIES A 7.2% RISK OF MORBIDITY AND 13.1% RISK OF MORTALITY IN THE US. STARLIGHT CARDIOVASCULAR PROPOSES CREATING AND COMMERCIALIZING THE FIRST FDA-APPROVED DUCTUS ARTERIOSUS STENT THAT IS SPECIFICALLY DESIGNED TO ADDRESS THE CHALLENGES FACING TREATING PHYSICIANS, INCLUDING A RIGHT-SIZED DELIVERY SYSTEM, END-TO-END COVERAGE OF THE DUCTUS, NAVIGATION AND DEPLOYMENT THROUGH TORTUOUS DUCTUS ANATOMY, AND PRECISE PLACEMENT TO AVOID STENT PROTRUSION INTO THE AORTA AND PULMONARY ARTERIES. A STENT DESIGNED AND TESTED SPECIFICALLY FOR THIS PURPOSE HAS THE POTENTIAL TO DECREASE REINTERVENTIONS, MORBIDITY, AND POTENTIALLY MORTALITY FOR BABIES WITH DUCTAL-DEPENDENT CIRCULATION. THIS PHASE I PROJECT INVOLVES DEVELOPING TEST FIXTURES, STENT PROTOTYPING AND TESTING, AND A PRECLINICAL ANIMAL STUDY. DUE TO THE VARIABILITY OF DUCTUS ANATOMY, AT LEAST SIX BENCHTOP ANATOMICAL MODELS WILL BE DEVELOPED FROM 3D COMPUTATIONAL MODELS OF PATIENT-SPECIFIC ANATOMY. STARLIGHT'S STENT AND DELIVERY SYSTEMS WILL THEN UNDERGO NUMEROUS ITERATIONS OF DESIGNING, BUILDING AND BENCHTOP TESTING USING THE ANATOMICAL MODELS TO OPTIMIZE THE STENT DESIGNS FOR DELIVERABILITY, PLACEMENT ACCURACY AND RADIAL FORCE TAILORED TO THE CHALLENGING DUCTUS ANATOMY. TO SELECT THE FINAL STENT AND DELIVERY SYSTEM DESIGN, THE MOST PROMISING STENT DESIGNS WILL BE IMPLANTED ACUTELY IN NEONATAL LAMBS TO EVALUATE THEIR PERFORMANCE IN VIVO. THIS PHASE I PROJECT WILL RESULT IN THE ULTIMATE SELECTION OF THE BEST DUCTUS ARTERIOSUS STENT AND DELIVERY SYSTEM DESIGN TO UNDERGO DESIGN VALIDATION TESTING IN PHASE II IN PREPARATION FOR FDA APPROVAL.

DEVELOPMENT OF AN INTRAVASCULAR CIRCULATORY SUPPORT DEVICE FOR HIGH-RISK FOR PERCUTANEOUS CORONARY INTERVENTION AND CARDIOGENIC SHOCK

CONTINUUM OF CARE PROGRAM

PURPOSE: THE PURPOSE OF HUD’S COMPREHENSIVE HOUSING COUNSELING (CHC) GRANT IS TO PROVIDE DIRECT FUNDING SUPPORT TO HUD’S NATION-WIDE NETWORK OF APPROVED HOUSING COUNSELING AGENCIES. FOR MORE INFORMATION ABOUT THE COMPREHENSIVE HOUSING COUNSELING GRANT PROGRAM, SEE HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/HOUSING/SFH/HCC.; ACTIVITIES TO BE PERFORMED: HOUSING COUNSELING ACTIVITIES INCLUDE PROVIDING INFORMATION, ADVICE, AND TOOLS FOR CONSUMERS SEEKING, FINANCING, MAINTAINING, RENTING, OR OWNING A HOME. AGENCIES ALSO ASSIST THOSE FACING HOMELESSNESS AND HOMEOWNERS IN NEED OF FORECLOSURE ASSISTANCE. THE HOUSING COUNSELING ACTIVITY TYPES THAT CAN BE REIMBURSED BY THE CHC GRANT INCLUDE ALL APPROVED HOUSING COUNSELING, EDUCATION, AND OUTREACH TOPICS LISTED IN THE CURRENT. HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/ADMINISTRATION/HUDCLIPS/HANDBOOKS/HSGH/7610.1. THIS INCLUDES, BUT IS NOT LIMITED TO, PRE-PURCHASE/HOME BUYING COUNSELING, RESOLVING, OR PREVENTING FORWARD OR REVERSE MORTGAGE DELINQUENCY OR DEFAULT COUNSELING, AND NON-DELINQUENCY POST-PURCHASE COUNSELING. GRANTEES ARE REQUIRED TO DEMONSTRATE, THROUGH THE CURRENT FORM HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/ADMINISTRATION/HUDCLIPS/FORMS/HUD9, HOUSING COUNSELING AGENCY ACTIVITY REPORT, THE NUMBER OF HOUSEHOLDS THAT WERE COUNSELED BY ACTIVITY TYPE AND NUMBER OF HOUSEHOLDS THAT ATTENDED WORKSHOPS BY ACTIVITY TYPE DURING THE APPLICABLE FISCAL YEAR. HOUSING COUNSELING AGENCIES MAY ALSO BE SPECIFICALLY AWARDED TO PARTNER WITH A MINORITY-SERVING INSTITUTION (MSI) TO PROVIDE HOUSING COUNSELING TO THE MSI INSTITUTIONS’ COMMUNITIES AND EXPAND THESE INSTITUTIONS’ PARTNERSHIPS WITH HOUSING COUNSELING AGENCIES. OUTPUTS AND DELIVERABLES FOR THIS GRANT AWARD IS THE SAME AS THE PARAGRAPH DESCRIBED ABOVE, HOWEVER, GRANTEES ARE REQUIRED TO PARTNER WITH A MSI TO PROVIDE THOSE ACTIVITIES. ; EXPECTED OUTCOMES: THE QUANTIFIABLE OUTCOMES FOR THE CHC GRANT INCLUDE, BUT ARE NOT LIMITED TO, THE NUMBER OF HOUSEHOLDS THAT GAINED ACCESS TO HOUSING RESOURCES; RECEIVED INFORMATION ON FAIR HOUSING, FAIR LENDING, AND/OR ACCESSIBILITY RIGHTS; IMPROVED CURRENT LIVING CONDITIONS; PURCHASED HOUSING; RECEIVED A REVERSE MORTGAGE; PREVENTED OR RESOLVED A MORTGAGE DEFAULT; AND RECEIVED A LOAN MODIFICATION. ALL POSSIBLE OUTCOMES ARE LISTED IN SECTION 10 OF THE CURRENT FORM HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/ADMINISTRATION/HUDCLIPS/FORMS/HUD9, HOUSING COUNSELING AGENCY ACTIVITY REPORT.; INTENDED BENEFICIARIES: INDIVIDUALS, GROUPS OF INDIVIDUALS, AND FAMILIES WHO ARE RENTERS, TENANTS, HOMEOWNERS, AND HOME BUYERS UNDER HUD, CONVENTIONAL, AND OTHER GOVERNMENT PROGRAMS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME - ABSTRACT STARLIGHT CARDIOVASCULAR IS DEVELOPING WHAT WILL BE THE FIRST FDA APPROVED PERCUTANEOUS FLOW RESTRICTOR TO REPLACE SURGICAL BANDING IN CONGENITAL HEART DEFECTS (CHD), INCLUDING HYPOPLASTIC LEFT HEART SYNDROME (HLHS). THE POTENTIAL WORLDWIDE MARKET FOR THE STARLIGHT FLOW RESTRICTOR IS OVER $200M. APPROXIMATELY 1,000 AMERICANS ARE BORN EACH YEAR WITH HYPOPLASTIC LEFT HEART SYNDROME (HLHS), A CONDITION WHERE THE LEFT VENTRICLE IS SEVERELY UNDERDEVELOPED OR BARELY PRESENT. BABIES BORN WITH HLHS REQUIRE PALLIATION SURGERY, COMMONLY A NORWOOD PROCEDURE, WITHIN DAYS AFTER BIRTH TO SURVIVE, SUBJECTING THE NEONATE TO CARDIOPULMONARY BYPASS AND A COSTLY, INVASIVE SURGERY. A HYBRID (HALF SURGICAL AND HALF PERCUTANEOUS) PALLIATION PROCEDURE EXISTS AS AN ALTERNATIVE, HOWEVER A LIMITATION OF THE HYBRID PROCEDURE IS RELIABLE BRANCH PULMONARY ARTERY BANDING. BRANCH PULMONARY ARTERY BANDING REQUIRES AN OPEN SURGERY AND CAN INTERFERE WITH PULMONARY ARTERY GROWTH, NECESSITATING PULMONARY ARTERY RECONSTRUCTION SURGERY. ATTEMPTS AT MODIFYING EXISTING DEVICES TO CREATE PERCUTANEOUS FLOW RESTRICTORS TO REPLACE SURGICAL BANDING PRODUCED SOME PROMISING CLINICAL RESULTS. HOWEVER USE OF THESE MODIFIED DEVICES IS LIMITED BY TECHNICAL CHALLENGES SUCH AS LARGE AND STIFF DELIVERY SYSTEMS, LONG IMPLANT LENGTHS, LACK OF ADJUSTABILITY AND RELIABILITY, AND DESIGNS THAT INCREASE THROMBOSIS RISK. STARLIGHT CARDIOVASCULAR IS DEVELOPING A PERCUTANEOUS AND ADJUSTABLE BRANCH PULMONARY ARTERY BLOOD FLOW RESTRICTOR TO REPLACE SURGICAL BANDING. OUR DEVICE ADDRESSES THE SHORTCOMINGS FROM PREVIOUS ATTEMPTS AT A PERCUTANEOUS FLOW RESTRICTOR, BY PROVIDING SAFE VENOUS IMPLANT DELIVERY, RELIABLE FLOW REDUCTION, PERCUTANEOUS ADJUSTABILITY, BENEFICIAL HEMODYNAMICS, AND A SHORT AND WELL ANCHORED IMPLANT DESIGN THAT IS REMOVABLE. THESE PULMONARY FLOW RESTRICTORS DESIGNED FOR HLHS CAN BE MODIFIED TO ALSO REPLACE MAIN PULMONARY ARTERY BANDING, MORE THAN DOUBLING THE NUMBER OF PATIENTS WHO COULD BENEFIT. THIS PHASE I SBIR GRANT WILL CONSIST OF COMPUTATIONAL FLUID DYNAMICS MODELING AND TESTING TO INFORM DEVICE DESIGN, BENCHTOP MODEL DEVELOPMENT, AND FINAL DEVICE DESIGN SELECTION THROUGH END-USER BENCHTOP TESTING BY PEDIATRIC INTERVENTIONAL CARDIOLOGISTS. SUCCESSFUL COMPLETION OF THIS PROJECT WILL PRODUCE A FINAL DEVICE DESIGN THAT IS READY FOR ANIMAL TESTING, DESIGN REFINEMENT, AND VERIFICATION AND VALIDATION TESTING IN PHASE II, WHICH WILL PREPARE THE FLOW RESTRICTOR DEVICE FOR A CLINICAL TRIAL, FDA HUMANITARIAN DEVICE EXEMPTION APPROVAL, AND COMMERCIALIZATION.

2012 TITLE X FAMILY PLANNING TRAINING AND TECHNICAL ASSISTANCE COOPERATIVE AGREEMENT FOA - PART B STD RELATED RH, PREVENTION TRAINING AND TA CENTERS

MATERNAL, INFANT & REPRODUCTIVE HEALTH: NATIONAL/STATE COALITION CAPACITY

REAP ENERGY EFFICIENCY IMPROVEMENT (EEI) GRANT UNRESTRICTED AMOUNT

NATURAL FAMILY PLANNING IN REGION X TITLE X CLINICS

FORMULATION AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF DEFERIPRONE FOR PREVENTION OF CHRONIC HEART FAILURE FOLLOWING HEMORRHAGIC MYOCARDIAL INFARCTION. - PROBLEM: APPROXIMATELY 50% OF MYOCARDIAL INFARCTION (MI) PATIENTS PROGRESS TO CHRONIC HEART FAILURE (CHF) POST-MI WITH A 5-YEAR MORTALITY RATE OF ~50% (>300,000 US DEATHS ANNUALLY). RECENT STUDIES HAVE ELUCIDATED AN OBLIGATE MECHANISM FOR PROGRESSION TO CHF AND NEW THERAPEUTIC OPPORTUNITIES. THE DATA INDICATE: 1) THAT HEMORRHAGE IS ASSOCIATED WITH LARGER MIS; 2) WHEN NORMALIZED FOR INFARCT SIZE, PATIENTS WITH HEMORRHAGIC MIS (HMIS) ARE AT GREATER RISK FOR CHF; AND 3) INTRAMYOCARDIAL IRON FROM HEMORRHAGE PERSISTS FOR YEARS AND DRIVES PERSISTENT MACROPHAGE RECRUITMENT, INFLAMMATION, FAT DEPOSITION, AND LOSS OF HEART FUNCTION. EXTENSIVE DATA DEMONSTRATE THAT DEFERIPRONE (A GENERIC IRON CHELATOR FDA APPROVED FOR IRON OVERLOAD IN THALASSEMIA PATIENTS) RENDERS IRON FUNCTIONALLY INERT, SUPPRESSES FAT DEPOSITION, REDUCES IRON WITHIN HMI TERRITORIES, AND SUPPORTS ANATOMICAL AND FUNCTIONAL RECOVERY AWAY FROM CHF IN A LARGE ANIMAL MODEL OF HMI. YET, DEFERIPRONE HAS AN EXCEPTIONALLY SHORT HALF-LIFE (1-2 HOURS). EVEN GIVEN 2- TO 3-TIMES DAILY, LARGE GAPS IN BLOOD LEVELS (EXPOSURE) OF DEFERIPRONE ARE EVIDENT, WITH IMPLICATIONS FOR GAPS IN SUPPRESSION OF DISEASE PROGRESSION AND IRON REMOVAL. ALSO, DEFERIPRONE HAS LOW BIOAVAILABILITY DUE TO ~70% FIRST-PASS METABOLISM IN THE LIVER TO THE INACTIVE 3-O- GLUCURONIDE METABOLITE, WHICH MAY BE ASSOCIATED WITH AT LEAST SOME (POSSIBLY MOST?) SIDE EFFECTS. SOLUTION: WE PROPOSE THAT SUBCUTANEOUS DELIVERY OF DEFERIPRONE USING AN INFUSION PUMP WILL PROVIDE CONTINUOUS BLOOD EXPOSURE TO MAINTAIN IRON IN ITS INERT STATE, WILL ENABLE CONTINUOUS IRON REMOVAL, AND WILL BYPASS FIRST PASS METABOLISM AND MINIMIZE EXPOSURE TO DEFERIPRONE’S PRIMARY METABOLITE. WE FURTHER PROPOSE THAT A LOWER DOSE OF DEFERIPRONE WILL PROVE HIGHLY EFFICACIOUS. IN PHASE I SBIR STUDIES, WE WILL ATTAIN PROOF OF CONCEPT THAT SUBCUTANEOUS (SC) ADMINISTRATION OF DEFERIPRONE IS EFFICIENT FOR DELIVERY OF DEFERIPRONE WHILE AVOIDING FIRST-PASS METABOLISM. IN PHASE II SBIR STUDIES, WE WILL EVALUATE ADMINISTRATION USING AS INFUSION PUMP, WE WILL DETERMINE THE MINIMUM DOSE FOR MAXIMAL EFFICACY, AND WE WILL ATTAIN INITIAL SAFETY DATA. AIM 1: WE WILL PREPARE DEFERIPRONE FROM AVAILABLE API SOURCES FOR SUBCUTANEOUS DELIVERY USING ESTABLISHED METHODS FOR OPTIMAL PATIENT COMFORT AND COMPLIANCE. PURITY OF THE API, ORAL, IV, AND SC DRUG WILL BE VERIFIED USING PUBLISHED HPLC METHODS AND WE WILL PERFORM PRELIMINARY 1-MONTH DRUG STABILITY AT AMBIENT AND ACCELERATED STORAGE CONDITIONS. AIM 2: WE WILL ESTABLISH LC/MS METHODS TO QUANTITATE AND IDENTIFY DEFERIPRONE AND ITS METABOLITES AND PERFORM PHARMACOKINETIC ANALYSIS OF SC ADMINISTRATION AS COMPARED TO IV AND ORAL DELIVERY. WE ANTICIPATE >90% BIOAVAILABILITY OF SC DEFERIPRONE (COMPARED TO IV), NO FIRST-PASS METABOLISM, AND DOSE- LINEARITY FOLLOWING SC ADMINISTRATION. IMPACT: FOREMOST, THIS STUDY HOLDS THE PROMISE TO BE THE FIRST DRUG CAPABLE OF REMOVING AN OBLIGATE DRIVER OF CHF IN POST HMI PATIENTS. THE PRODUCT FURTHER HOLDS THE PROMISE TO REDUCE SIDE-EFFECTS, MAINTAIN MORE PATIENTS ON THERAPY, AND ULTIMATELY ENHANCE QUALITY OF LIFE AND LIFE EXPECTANCY OF HUNDREDS OF THOUSANDS OF POST-HMI PATIENTS EACH YEAR.

CONTINUUM OF CARE PROGRAM

SPC TENANT BASED RA

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

LEARNING, ANALYTICS AND KNOWLEDGE MANAGEMENT SUPPORT IN KENYA AND EAST AFRICA REGION

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

PURPOSE: TO PROMOTE ECONOMIC REVITALIZATION AND COMMUNITY DEVELOPMENT THROUGH TECHNICAL ASSISTANCE AWARDS TO BUILD THE CAPACITY OF COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS) AND EMERGING CDFIS. PLANNED ACTIVITIES TECHNICAL ASSISTANCE MUST BE USED FOR THE FOLLOWING ELIGIBLE ACTIVITIES SUBJECT TO THE APPLICABLE PROVISIONS OF THE UNIFORM REQUIREMENTS COMPENSATION PERSONAL SERVICES, COMPENSATION FRINGE BENEFITS, PROFESSIONAL SERVICE COSTS, TRAVEL COSTS, TRAINING AND EDUCATION COSTS, EQUIPMENT, SUPPLIES, AND INCORPORATION COSTS (SPONSORING ENTITIES ONLY). END GOALS: THE GOAL OF THE TECHNICAL ASSISTANCE IS TO BUILD CERTIFIED AND EMERGING CDFI’S ORGANIZATIONAL CAPACITY TO SERVE ELIGIBLE MARKETS AND/OR THEIR TARGET MARKETS, IN ORDER TO SERVE LOW INCOME PEOPLE, AND COMMUNITIES ACROSS THE NATION THAT LACK ADEQUATE ACCESS TO AFFORDABLE FINANCIAL PRODUCTS AND FINANCIAL SERVICES. BENEFICIARIES: PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, OTHER PRIVATE INSTITUTION/ORGANIZATION INVESTMENT AREAS AND TARGETED POPULATIONS, AS DEFINED IN 12 C.F.R. 1805. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: NOT APPLICABLE. REASON/PURPOSE OF MODIFICATION: NOT APPLICABLE.

JORDAN WATERSHED PROJECT

PREVENTING OPIOID MISUSE AMONG GIRLS COMMUNITY OF PRACTICE (COP)

SPC TENANT BASED RA

INTEGRATING HIV & OTHER PREVENTION SERVICES INTO REPRODUCTIVE HEALTH

SBIR PHASE I: TRUSTWORTHY AND AUTOMATED ELECTROCARDIOGRAM ANALYSIS -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT IS TO IMPROVE OUTCOMES FOR PATIENTS WITH HEART PROBLEMS. THIS PROJECT WILL DEVELOP AN AI SOLUTION FOR THE AUTOMATIC INTERPRETATION OF ELECTROCARDIOGRAMS (ECG) TO DETECT AND PREDICT IRREGULAR HEARTBEATS. THIS WILL BENEFIT PATIENTS WITH CARDIAC ARRHYTHMIAS AND WILL REDUCE SPENDING ON CARDIOVASCULAR DISEASE. THIS SMALL BUSINESS INNOVATION RESEARCH PHASE (SBIR) I PROJECT AIMS TO REFINE EXISTING DEEP LEARNING-BASED DETECTION ALGORITHMS, DEVELOP METHODS FOR THE PREDICTION OF THE ONSET OF CARDIAC ARRHYTHMIAS, DEVELOP INTERPRETABLE AND EXPLAINABLE TOOLS FOR CLINICIANS, AND DEVELOP A WEB-BASED SOFTWARE TOOL FOR USERS TO DEVELOP INSIGHTS FROM ECG SIGNALS. THIS PROJECT LEVERAGES ARTIFICIAL INTELLIGENCE TECHNOLOGIES, INCLUDING DEEP LEARNING AND NATURAL LANGUAGE PROCESSING, AS WELL AS SIGNAL PROCESSING TECHNIQUES FOR A TRUSTWORTHY AND AUTOMATED ECG ANALYSIS TOOL FOR PREDICTION AND DETECTION THE TECHNIQUES REPRESENT MULTIMODAL APPROACHES DERIVED FROM VARIOUS DATA SOURCES, INCLUDING THE ECG SIGNALS AND ELECTRONIC HEALTH RECORD (EHR) DOCUMENTATION OF CLINICIAN ECG INTERPRETATIONS. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

ALPHA B CRYSTALLIN AS A NOVEL THERAPEUTIC FOR SIRS AND SEPSIS

CONTINUUM OF CARE PROGRAM

STTR PHASE I: DEVELOPMENT OF A WEARABLE LONG-TERM MONITOR FOR CARDIAC ARRHYTHMIA

SPC-RENEWAL TENT BRA

NEXT GENERATION REGENERATIVE THERAPY WITH PIM-1 ENHANCED CARDIAC PROGENITOR CELLS

DIRECTED GRANTS

AMERICAN RESCUE PLAN

THE SURVIVAL FROM ACUTE MYOCARDIAL INFARCTION (SAMI) INITIATIVE

SBIR PHASE I: MOTION ARTIFACT MANAGEMENT FOR ACCURATE AND CONTINUOUS NON-INVASIVE BLOOD PRESSURE MONITORING -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT IS TO ENABLE ACCURATE, CONTINUOUS, AND WIDELY AVAILABLE BLOOD PRESSURE (BP) MEASUREMENTS. THE CURRENT STANDARD OF CARE IS SINGLE POINT-IN-TIME BP MONITORING USING AN ARM-CUFF DEVICE. THIS METHOD HAS TWO BASIC DRAWBACKS: INACCURACY AND THE INABILITY TO MEASURE BP CONTINUOUSLY OVER 24 HOURS, LIMITING CLINICAL INSIGHT. THE MAJOR CHALLENGE TO CONTINUOUS RELIABLE BP MEASUREMENTS IS MOTION ARTIFACTS DUE TO MOVEMENT, SUCH AS AN ARM GESTURES. THIS PROJECT WILL ADVANCE DEVELOPMENT OF A NOVEL DEVICE FOR NON-INVASIVE BEAT-TO-BEAT BP MEASUREMENT IN A CUFF-LESS, WRIST-WEARABLE DEVICE. ACCURATE 24-HOUR BP MEASUREMENT AT HOME AND OTHER SETTINGS WILL SIGNIFICANTLY IMPROVE OUTCOMES FOR 1.5 BILLION PEOPLE GLOBALLY WHO SUFFER FROM CHRONIC HIGH BP OR HYPERTENSION, A LEADING CAUSE OF STROKE AND HEART ATTACKS. OTHER CHRONIC CONDITIONS BENEFITING FROM ACCURATE 24-HOUR BP MEASUREMENT INCLUDE SLEEP APNEA, HEART AND RENAL FAILURE, AND DEMENTIA. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT UTILIZES A HIGHLY SENSITIVE OPTOMECHANICAL SENSOR TO CAPTURE VIDEO IMAGES OF SKIN DISPLACEMENT OVER THE RADIAL ARTERY TO INDEPENDENTLY MEASURE SYSTOLIC AND DIASTOLIC BP CONTINUOUSLY. THE TECHNOLOGY MEASURES BP ACCURATELY AND CONTINUOUSLY IN STATIONARY CONDITIONS (I.E., SEATED OR LYING DOWN). THE GOAL OF THIS PROJECT IS TO IDENTIFY, CHARACTERIZE AND ADDRESS MOTION ARTIFACTS THAT OCCUR DURING ROUTINE USE IN HOSPITAL INTENSIVE CARE UNITS AND OPERATING ROOMS. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

DEVELOPMENT OF A SUTURELESS LVAD OUTFLOW GRAFT ANASTOMOTIC QUICK-CONNECT SYSTEM

DEVELOPMENT OF A PARTIAL OCCLUSION DEVICE TO AID IN CORING AND ANASTOMSIS OF THE AORTA

LOW ENERGY VENTRICULAR DEFIBRILLATOR

RESIDENT OPPORTUNITY AND SUPPORTIVE SERVICES - SERVICE COORDINATORS

CONTINUUM OF CARE PROGRAM

METHOD FOR RAPID NON-INVASIVE ASSESSMENT OF CORONARY STENOSIS - VCARDIO, INC METHOD FOR RAPID NON-INVASIVE ASSESSMENT OF CORONARY STENOSIS PROJECT SUMMARY WE HAVE DEVELOPED A NON-INVASIVE TECHNIQUE FOR QUANTIFYING THE SEVERITY OF STENOSIS (BLOCKAGE) IN CORONARY ARTERIES. ONE MILLION INVASIVE CORONARY ANGIOGRAPHY (ICA) PROCEDURES ARE PERFORMED EVERY YEAR IN PATIENTS WHO PRESENT WITH CHEST PAIN OR ARE KNOWN TO HAVE STABLE CORONARY ARTERY DISEASE (CAD). THE GOAL OF THE PROCEDURE IS TO DETERMINE IF THERE IS ANY SIGNIFICANT STENOSIS THAT LIMITS BLOOD FLOW TO THE HEART MUSCLE IN THE CORONARY ARTERIES. ALMOST HALF OF ICAS CULMINATE IN STENT PLACEMENT IN CORONARY ARTERIES IN ORDER TO RELIEVE THE BLOCKAGE OF BLOOD FLOW. THE CARDIOLOGIST PERFORMING THE PROCEDURE IN THE CATHETERIZATION LAB DETERMINES THE SIGNIFICANCE OF THE STENOSIS BY ONE OF TWO METHODS: EITHER BY VISUALLY ESTIMATING THE DEGREE OF STENOSIS (‘EYEBALLING’ THE STENOSIS), WHICH IS THE ROUTINE PRACTICE AND IS DONE IN THE MAJORITY OF PATIENTS, OR BY INVASIVELY MEASURING FRACTIONAL FLOW RESERVE (PRESSURE-WIRE FFR), WHICH IS THE GOLD STANDARD TEST. HOWEVER, PRESSURE- WIRE FFR IS ONLY PERFORMED IN 10-20% OF PATIENTS BECAUSE IT IS INVASIVE, EXPENSIVE, AND TIME- CONSUMING, AND REQUIRES MORE RADIATION AND CONTRAST EXPOSURE. THE PROPOSED TECHNOLOGY PROVIDES AN ACCURATE, HIGHLY SENSITIVE AND SPECIFIC, NON-INVASIVE METHOD TO ASSESS THE SIGNIFICANCE OF CORONARY STENOSIS THROUGH CORONARY ANGIOGRAPHY WITHOUT PRESSURE-WIRE FFR MEASUREMENT. WHEN PERFORMED IN REAL-TIME, UNDER 2 MINUTES, THIS ALLOWS THE CARDIOLOGIST TO MAKE AN INFORMED DECISION REGARDING STENT PLACEMENT. SUCH A METHOD WOULD DELIVER THE BENEFITS OF PRESSURE-WIRE FFR MEASUREMENT IN TERMS OF COST SAVINGS AND IMPROVEMENT IN PATIENT SYMPTOMS, WHILE AVOIDING DISADVANTAGES SUCH AS EXTRA COST FOR THE PROCEDURE AND TIME BURDEN. IT PERFORMS FAVORABLY COMPARED TO COMPETING TECHNOLOGY IN TERMS OF ACCURACY BUT IS SUPERIOR TO COMPETITION WITH REGARDS TO THE TIME REQUIRED TO RUN THE SOFTWARE. THIS ALLOWS US TO PROVIDE A TRULY REAL-TIME SOLUTION FOR QUANTIFICATION OF CORONARY STENOSIS. OUR APPROACH USES REDUCED ORDER MODELING METHODS TO MODEL CORONARY BLOOD FLOW ACROSS STENOTIC CORONARY LESIONS AND ASSESS THE DEGREE OF STENOSIS SEVERITY BY INCORPORATING RESIDENCE TIME OF BLOOD FLOW THROUGH THE STENOTIC SEGMENTS. THE MAJOR ADVANTAGE OF THIS APPROACH OVER THE COMPETING SOLUTIONS IS ITS POTENTIAL TO DELIVER A REAL-TIME VIRTUAL SOLUTION WITHIN SECONDS. ONCE IMPLEMENTED, THE SOLUTION WOULD MERGE SEAMLESSLY WITH THE CURRENT CATHETERIZATION LAB EQUIPMENT AND PROVIDE A REAL-TIME, OBJECTIVE TOOL FOR ASSESSMENT OF CORONARY LESIONS BY THE TREATING CARDIOLOGISTS. THE OBJECTIVE IS TO SCALE THE STUDY FROM AN INITIAL SUCCESSFUL 54 PATIENT STUDY UP TO 500 PATIENTS (400 PATIENTS IN DERIVATION COHORT AND 100 PATIENTS IN VALIDATION COHORT) BY CONDUCTING A RETROSPECTIVE STUDY IN PATIENTS WITH KNOWN CAD WHO HAVE UNDERGONE CORONARY ANGIOGRAPHY AND PRESSURE-WIRE FFR MEASUREMENT FOR CLINICAL INDICATIONS.

INTRAVESICAL CHITOSAN IL-12 THERAPY IN AN ORTHOTOPIC MOUSE BLADDER CANCER MODEL

A NOVEL POLYMERIC VALVE FOR TRANSCATHETER AORTIC VALVE REPLACEMENT

TO IMPROVE THE CAPACITIES OF PAKISTANI SMALL FARMERS AND FACLITATORS BY USING THE FARMER FIELD SCHOOL (FFS) APPROACH TOINTRODUCE TECHNIQUES THAT WILL PROMOTE THE REDUCTION IN POST-HARVEST LOSSES.

NON-INVASIVE WRIST-WATCH DEVICE FOR REMOTE MONITORING OF HEART FAILURE PATIENTS - ABSTRACT THE OBJECTIVE OF THIS STUDY IS TO PROVE THE FEASIBILITY OF AN INNOVATIVE DIAGNOSTIC DEVICE FOR THE DETECTION AND MONITORING OF WORSENING HEART FAILURE. HEART FAILURE AFFECTS 6.5 MILLION OF AMERICANS AND COST THE US OVER $30B A YEAR IN HEALTHCARE SERVICES, MEDICATIONS AND MISSED WORK. THESE COSTS ARE EXPECTED TO DOUBLE BY 2030. HEART FAILURE IS ASSOCIATED WITH HIGH HEALTHCARE UTILIZATION DUE TO FREQUENT HOSPITAL RE-ADMISSIONS. HEART FAILURE IS THE MOST COMMON DIAGNOSIS IN ALL HOSPITAL ADMISSIONS IN PATIENTS OVER 65. THE READMISSION RATE IS HIGH – OVER 20% BY 30 DAYS, AND 30% BY 90 DAYS POST-DISCHARGE. THERE IS A SIGNIFICANT NEED FOR IN-HOME NON-INVASIVE METHODS TO DETECT EARLY STAGES OF DESTABILIZATION IN HEART FAILURE. HEMODYNAMIC CONGESTION DEFINED AS INCREASING FILLING PRESSURES IN THE HEART TYPICALLY PRECEDES OTHER CLINICAL SYMPTOMS. DETECTION AND MONITORING OF HEMODYNAMIC CONGESTION OFFERS THE HEALTHCARE PROFESSIONALS AN OPPORTUNITY TO INTERVENE BY ADJUSTING THE MEDICATIONS AND TO PREVENT ACUTE HEART FAILURE EPISODES AND HOSPITALIZATIONS. THIS PILOT CLINICAL RESEARCH STUDY IS DESIGNED TO DEMONSTRATE THAT THE INNOVATIVE CORWATCH™ TECHNOLOGY IS EFFECTIVE IN DETECTING HEMODYNAMIC CONGESTION IN HEART FAILURE. CORWATCH™ DETECTS INCREASES IN CENTRAL VENOUS AND RIGHT ATRIAL PRESSURES WHICH ARE CONCORDANT WITH INCREASE IN THE LEFT HEART FILLING PRESSURES. ADULT HEART FAILURE PATIENTS UNDERGOING CARDIAC CATHETERIZATION IN A CARDIAC LAB WILL BE RECRUITED FOR THIS STUDY. THE SPECIFIC AIMS ARE TO FURTHER DEVELOP CORWATCH™ DEVICES FOR THE CLINICAL TRIAL; AND TO DEMONSTRATE A GOOD AGREEMENT BETWEEN THE CORWATCH™ TECHNOLOGY AND THE CARDIAC PRESSURES MEASURED WITH THE GOLD STANDARD – SWAN GANZ CATHETER. IF THIS RESEARCH STUDY SHOWS THE EFFECTIVENESS OF THE PROPOSED DIAGNOSTIC APPROACH, CORWATCH™ DEVICE CAN POTENTIALLY BE INTEGRATED INTO CLINICAL PRACTICE OF CARDIOLOGISTS AND OTHER PHYSICIANS AS AN EASY-TO-USE IN-HOME NON-INVASIVE DEVICE FOR MONITORING OF HEART FAILURE. CORWATCH™ WILL OFFER EARLY WARNINGS OF WORSENING HEART FAILURE AND AID HEALTHCARE PROFESSIONALS IN PREVENTION OF PATIENT’S DESTABILIZATION THAT CAN LEAD TO ACUTE HEART FAILURE EPISODE AND HOSPITALIZATION. THEREFORE, CORWATCH™ HAS A POTENTIAL TO REDUCE THE HEALTHCARE COSTS AND TO IMPROVE QUALITY OF LIFE OF HEART FAILURE PATIENTS.

AN INTEGRATED GENETIC-EPIGENETIC TOOL FOR THE PREDICTION OF CHD INCIDENCE IN AFRICAN-AMERICANS

JOBS-PLUS PILOT INITIATIVE

HOUSING COUNSELING ASSISTANCE PROGRAM

PROMOTING EQUITY THROUGH EXPANSION OF REGISTRIES.

THERAPEUTIC AMYLOID FIBRILS

HOUSING COUNSELING ASSISTANCE PROGRAM

RESIDENT OPPORTUNITY AND SUPPORTIVE SERVICES - SERVICE COORDINATORS

ENHANCED SYSTEM FOR ATRIAL DEFIBRILLATION

SPC-RENEWAL TENT BRA

CONTINUUM OF CARE PROGRAM

PURPOSE: THE PURPOSE OF HUD’S COMPREHENSIVE HOUSING COUNSELING (CHC) GRANT IS TO PROVIDE DIRECT FUNDING SUPPORT TO HUD’S NATION-WIDE NETWORK OF APPROVED HOUSING COUNSELING AGENCIES. FOR MORE INFORMATION ABOUT THE COMPREHENSIVE HOUSING COUNSELING GRANT PROGRAM, SEE HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/HOUSING/SFH/HCC.; ACTIVITIES TO BE PERFORMED: HOUSING COUNSELING ACTIVITIES INCLUDE PROVIDING INFORMATION, ADVICE, AND TOOLS FOR CONSUMERS SEEKING, FINANCING, MAINTAINING, RENTING, OR OWNING A HOME. AGENCIES ALSO ASSIST THOSE FACING HOMELESSNESS AND HOMEOWNERS IN NEED OF FORECLOSURE ASSISTANCE. THE HOUSING COUNSELING ACTIVITY TYPES THAT CAN BE REIMBURSED BY THE CHC GRANT INCLUDE ALL APPROVED HOUSING COUNSELING, EDUCATION, AND OUTREACH TOPICS LISTED IN THE CURRENT. HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/ADMINISTRATION/HUDCLIPS/HANDBOOKS/HSGH/7610.1. THIS INCLUDES, BUT IS NOT LIMITED TO, PRE-PURCHASE/HOME BUYING COUNSELING, RESOLVING, OR PREVENTING FORWARD OR REVERSE MORTGAGE DELINQUENCY OR DEFAULT COUNSELING, AND NON-DELINQUENCY POST-PURCHASE COUNSELING. GRANTEES ARE REQUIRED TO DEMONSTRATE, THROUGH THE CURRENT FORM HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/ADMINISTRATION/HUDCLIPS/FORMS/HUD9, HOUSING COUNSELING AGENCY ACTIVITY REPORT, THE NUMBER OF HOUSEHOLDS THAT WERE COUNSELED BY ACTIVITY TYPE AND NUMBER OF HOUSEHOLDS THAT ATTENDED WORKSHOPS BY ACTIVITY TYPE DURING THE APPLICABLE FISCAL YEAR. HOUSING COUNSELING AGENCIES MAY ALSO BE SPECIFICALLY AWARDED TO PARTNER WITH A MINORITY-SERVING INSTITUTION (MSI) TO PROVIDE HOUSING COUNSELING TO THE MSI INSTITUTIONS’ COMMUNITIES AND EXPAND THESE INSTITUTIONS’ PARTNERSHIPS WITH HOUSING COUNSELING AGENCIES. OUTPUTS AND DELIVERABLES FOR THIS GRANT AWARD IS THE SAME AS THE PARAGRAPH DESCRIBED ABOVE, HOWEVER, GRANTEES ARE REQUIRED TO PARTNER WITH A MSI TO PROVIDE THOSE ACTIVITIES. ; EXPECTED OUTCOMES: THE QUANTIFIABLE OUTCOMES FOR THE CHC GRANT INCLUDE, BUT ARE NOT LIMITED TO, THE NUMBER OF HOUSEHOLDS THAT GAINED ACCESS TO HOUSING RESOURCES; RECEIVED INFORMATION ON FAIR HOUSING, FAIR LENDING, AND/OR ACCESSIBILITY RIGHTS; IMPROVED CURRENT LIVING CONDITIONS; PURCHASED HOUSING; RECEIVED A REVERSE MORTGAGE; PREVENTED OR RESOLVED A MORTGAGE DEFAULT; AND RECEIVED A LOAN MODIFICATION. ALL POSSIBLE OUTCOMES ARE LISTED IN SECTION 10 OF THE CURRENT FORM HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/ADMINISTRATION/HUDCLIPS/FORMS/HUD9, HOUSING COUNSELING AGENCY ACTIVITY REPORT.; INTENDED BENEFICIARIES: INDIVIDUALS, GROUPS OF INDIVIDUALS, AND FAMILIES WHO ARE RENTERS, TENANTS, HOMEOWNERS, AND HOME BUYERS UNDER HUD, CONVENTIONAL, AND OTHER GOVERNMENT PROGRAMS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

RESIDENT OPPORTUNITY AND SUPPORTIVE SERVICES - SERVICE COORDINATORS

DEVELOPMENT OF A MATRIX-BASED PLATFORM FOR THE COLLECTION AND STORAGE OF NUCLEIC

HOUSING COUNSELING ASSISTANCE PROGRAM

HOUSING COUNSELING ASSISTANCE PROGRAM

CONTINUUM OF CARE PROGRAM

HOUSING COUNSELING ASSISTANCE PROGRAM

R&D, SCIENCE AND ENGINEERING, IN THE AREA OF MECHANICAL

CONTINUUM OF CARE PROGRAM

PROTOTYPE CATHETER FOR IN VIVO HIGH-RESOLUTION CARDIAC FLUORESCENCE MAPPING

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

HOUSING COUNSELING ASSISTANCE PROGRAM

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

SBIR PHASE I: USE OF AUTOMATED MULTIPARAMETRIC STRAIN ANALYSIS TECHNOLOGY (MPS) AS A DIAGNOSTIC TEST FOR HEART DISEASE

TOWARDS VIRTUAL LABORATORY FOR OPTIMAL PATIENT-SPECIFIC CARDIAC RESYNCHRONIZATION

JORDAN WATERSHED RESTORATION

SPC-RENEWAL TENT BRA

RETIRED AND SENIOR VOLUNTEER PROGRAM

SPC-RENEWAL TENT BRA

IMPACT AID PROGRAM TITLE VIII SECTION 8003 AND SECTION 8007(A)

HOUSING COUNSELING ASSISTANCE PROGRAM

CONTINUUM OF CARE PROGRAM

WASTE DISPOSAL GRANTS - REGULAR

INTEGRATION OF GERIATRICS PRINCIPLES INTO THE CARE OF OLDER ADULTS WITH CARDIOVAS

FIRST LONG TERM PERCUTANEOUS NON-SURGICAL LEFT VENTRICULAR ASSIST DEVICE

DOMESTIC WATER GRANTS - REGULAR

SPC TENANT BASED RA

ASSISTANCE TO FIREFIGHTERS GRANTS

NICOP - SOCIAL COMPLEXITY AND CRITICAL STATES OF SOCIETY: FROM UNDERLYING SOCIAL MECHANISMS TO POLITICAL CRISES IN CHILE.

CONTINUUM OF CARE PROGRAM

THE INSTITUTE FOR DISABILITY STUDIES AT THE VISCARDI CENTER WILL PROMOTE A CULTURE OF DISABILITY EQUITY AND INCLUSION FOR PEOPLE WITH DISABILITIES THROUGH EDUCATION AND INTERACTIVE EXHIBITS.

SBIR PHASE I: DEVELOPMENT OF DEVICE INTENDED TO DIRECT GROWTH OF NEW BLOOD VESSELS WITHIN A PATIENT FOR TREATMENT OF CARDIOVASCULAR DISEASES

SBIR PHASE I: A MOBILE APPLICATION FOR DETECTING ATRIAL FIBRILLATION

SBIR PHASE I: SYSTEM FOR CREATION AND USE OF REALISTIC CARDIAC ELECTROMECHANICAL SIMULATION MODELS

CONTINUUM OF CARE PROGRAM

TELEMEDICINE GRANT

STREAMBANK STABILIZATION FOR DSR 5107-001 CARDERVIEW UD HILL ROAD 5107 EWP PROJECT; EZFG ID: 6000013221

CELL RETENTION AND BIODISTRIBUTION AFTER TRANSENDOCARDIAL DELIVERY IN CARDIOVASCU

CONTINUUM OF CARE PROGRAM

HEERF-STRENGTHENING INSTITUTIONS PROGRAM

CONTINUUM OF CARE PROGRAM

ASSISTANCE TO FIREFIGHTERS GRANT

CONTINUUM OF CARE PROGRAM

PURPOSE: TO PROMOTE ECONOMIC REVITALIZATION AND COMMUNITY DEVELOPMENT THROUGH TECHNICAL ASSISTANCE AWARDS TO BUILD THE CAPACITY OF COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS) AND EMERGING CDFIS. PLANNED ACTIVITIES TECHNICAL ASSISTANCE MUST BE USED FOR THE FOLLOWING ELIGIBLE ACTIVITIES SUBJECT TO THE APPLICABLE PROVISIONS OF THE UNIFORM REQUIREMENTS COMPENSATION PERSONAL SERVICES, COMPENSATION FRINGE BENEFITS, PROFESSIONAL SERVICE COSTS, TRAVEL COSTS, TRAINING AND EDUCATION COSTS, EQUIPMENT, SUPPLIES, AND INCORPORATION COSTS (SPONSORING ENTITIES ONLY). END GOALS: THE GOAL OF THE TECHNICAL ASSISTANCE IS TO BUILD CERTIFIED AND EMERGING CDFI’S ORGANIZATIONAL CAPACITY TO SERVE ELIGIBLE MARKETS AND/OR THEIR TARGET MARKETS, IN ORDER TO SERVE LOW INCOME PEOPLE, AND COMMUNITIES ACROSS THE NATION THAT LACK ADEQUATE ACCESS TO AFFORDABLE FINANCIAL PRODUCTS AND FINANCIAL SERVICES. BENEFICIARIES: PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, OTHER PRIVATE INSTITUTION/ORGANIZATION INVESTMENT AREAS AND TARGETED POPULATIONS, AS DEFINED IN 12 C.F.R. 1805. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: NOT APPLICABLE. REASON/PURPOSE OF MODIFICATION: NOT APPLICABLE.

CONTINUUM OF CARE PROGRAM

QUANTITATIVE I-123 CARDIAC SPECT USING A NOVEL SPECTRAL FITTING METHOD FOR HIGH E

ASSISTANCE TO FIREFIGHTERS GRANT

306A EMERGENCY COMMUNITY WATER ASSISTANCE GRANTS - LIMIT $150,000 - REGULAR

CONTINUUM OF CARE PROGRAM

WATER ONLY FACILITY GRANTS (MANDATORY FARM BILL)

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

DETECTION OF OXIDIZED LDL IN PLASMA

ENDOMYOCARDIAL CATHETER DELIVERY OF ARTIFICIAL BIOPOLYMER MATRICES FOR ENHANCED C

THE SHARED DECISION MAKING (SDM)INITIATIVE

COMPREHENSIVE MR IMAGING OF ELDERLY VASCULAR FUNCTION